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1. INTRODUCTION 
1.1. Programmed cell death during animal development 
The German philosopher Arthur Schopenhauer mentioned that ―life is a constant process of 
dying‖ (1). This phrase describes accurately the crucial role that programmed cell death 
(PCD) plays in the life of an organism. Actually, the life of an animal depends on the correct 
and constant elimination of cells via PCD during its development and a continuous cell 
turnover during its adulthood. PCD consists of different cell-suicide pathways that get 
activated at specific time frames of animal development. Since the nineteenth century, the 
relevance of this mechanism has been recognized and it was proven to occur naturally in 
many tissues of both vertebrates and invertebrates (2).  
 
Jacobson and colleagues reviewed some of the main physiological functions of PCD. As 
shown in Fig. 1, it contributes to the sculpting of body parts in vertebrates, such as the 
formation of digits, inner ear and the four-chamber architecture of the heart. PCD is also 
involved in the deletion of tissues and organs, which are no longer needed in later 
developmental stages, or tissues that are not used in one sex. For example, the tadpole tail and 
intestine in amphibians are removed by PCD at older stages of development and the Müllerian 
duct that forms the uterus and oviducts in females is thought to be lost by PCD in males. PCD 
also adjusts cell numbers in organs where cells are overproduced. For example, in the 
vertebrate nervous system half of the neurons, which are generated in excess during 
embryonic development, are eliminated by PCD (3). It also eliminates more than 80% of 
oocytes prior to birth in human females (4, 5). In addition, it helps in the elimination of 
unwanted or dangerous cells such as self-reactive cells that could lead to autoimmunity in the 
human immune system or the removal of cells with unrepaired DNA damage, cell cycle 
perturbations or with fate and differentiation effects (3).  
 
Developmental malformations and some human diseases are linked to an aberrant PCD (6). A 
decrease in cell death may be related to diseases such as cancer, autoimmune disorders or 
viral infections (7). For example, most of the cancer cells have developed resistance to 
undergo apoptosis, one of the 13 different types of programmed cell death (8), due to 
overexpression of anti-apoptotic proteins such as B-cell lymphoma 2 (BCL-2) or B-cell 
lymphoma X long (BCL-XL) that prevents cell death (9, 10). New chemotherapeutic agents 
have been developed to promote cell death by activating specific genes of apoptosis. 
Similarly, in autoimmune disorders like systemic lupus and rheumatoid arthritis, a strategy to 
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reduce the lesion induced by auto-reactive T cells is to eliminate them from the circulation by 
adding death ligands from the tumor necrosis factor (TNF) receptor superfamily such as TNF-
α or Fas ligand (FasL). These proteins activate the death-receptor pathway leading to cell 
death (11). On the other hand, an excess in the cell death program is often associated with 
diseases such as human immunodeficiency virus (HIV), neurodegenerative diseases like 
Alzheimer’s disease, Parkinson, muscular atrophy, myocardial infarction and stroke. For 
instance, ischemia of both, neurons and cardiomyocytes induces programmed cell death (12).  
 
 
Fig. 1. Functions of programmed cell death during development. 
Programmed cell death has different functions during animal development such as (A) sculpting of tissues, (B) deletion of 
structures mainly in insect or amphibian metamorphosis, (C) participation in cell turnover and (D) elimination of dangerous 
cells. (Taken and adapted from (3, 5, 13-16). 
 
These diseases still represent a major health problem worldwide. According to the World 
Health Organization (WHO), cancer, neurodegenerative and cardiovascular diseases are still 
among the 10 top causes of death globally (17). Strikingly, ischemic heart disease is the 
world’s biggest killer, causing almost 9 million deaths in 2015 (18).  
 
It has been claimed that apoptosis is the major cause of cardiomyocyte’s demise in 
myocardial infarction, ischemic injury and heart failure (19). These studies suggest that 
inhibiting apoptosis might be a potent strategy for treating heart diseases. However, this is 
still controversial, as it is not clear which type or types of programmed cell death are present 
in healthy and diseased hearts (20). This is mainly due to a lack of sensitive detection methods 
that can track and identify cells undergoing PCD in the myocardium. In order to establish 
effective therapies for heart diseases, it is necessary to deeper understand the distinct 
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physiological roles, the diverse mechanisms and signaling pathways of PCD in both, the 
embryonic and the adult heart. This will serve as a basis for further elucidation of its role in 
the diseased heart.  
 
In the literature, it is still not specified if apoptosis, the most studied form of PCD, regulates 
the shaping and maturation of the mammalian heart (20, 21). Therefore, the focus of this work 
is to evaluate, if and to which extent this process is present during mouse development. For 
this, it is relevant to analyze the complex steps occurring during heart development in order to 
be able to evaluate in a second step, as to how apoptosis could be related to these 
developmental changes. The details of these processes will be described in the following 
paragraphs.  
 
1.2. Heart Development and apoptosis 
1.2.1. Formation of the heart  
The word ―heart‖ is defined in the dictionary as ―the essential or most vital part of something‖ 
(22). This meaning resembles the vital function of the heart in the body. It plays a key role in 
the circulation of nutrients and removal of waste during the early stages of life and if the heart 
stops beating or pumping blood in the body, life will end (23).  
 
The building of the heart involves a very detailed, sensitive and complex process. In order to 
form a proper and functional vertebrate heart, several morphological changes and different 
signaling pathways take place during development. These changes orchestrate the remodeling 
of the tubular heart into a mature four-chamber heart. Accurate heart organogenesis is the 
result of the interplay between proliferation, differentiation, cell growth and cell death (24). 
Alterations in these processes can lead to congenital heart diseases such as left ventricular 
non-compaction (LVNC), diastolic dysfunctions and arrhythmias and even might  be lethal 
for the embryo (25). According to Samsa and colleagues, the drastic changes in the 
mammalian's heart’s shape, known as cardiac chamber maturation, can be divided into three 
interconnected processes: formation of the trabeculae (myocardial projections), the 
establishment of the conduction system and compaction of the myocardium (25).  
 
The heart is the first organ to form and function in the embryo (26). It originates from 
mesodermal cells arising from the anterior part of the primitive streak in the embryo (Fig.  2). 
These cells migrate to the splanchnic (visceral) mesoderm in order to form the cardiac 
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crescent, which consists of two pools of cardiac progenitors. These cardiac precursors 
comprise the first and secondary heart fields (FHF, SHF) around embryonic day 7.5 (E7.5) in 
the mouse (27). As the embryo grows, the cardiac crescent fuses at the ventral midline to form 
the primitive heart tube at E8. The FHF will give rise to the left ventricle (LV), while the SHF 
will contribute to a large portion of the heart, including the outflow tract (OFT), right 
ventricle (RV), the sinus venosus (SV) and most of the atria (A). The early tubular mouse 
embryonic heart (between E7.5-8.5) is composed of an outer layer of myocardial cells 
framing it and an inner lining of endocardial cells derived from splanchnic mesoderm, 
separated by an extracellular matrix, which is better known as cardiac jelly (25, 28, 29). Even 
if in these early stages the heart lacks valves and a conduction system, it starts contracting and 
functioning as a peristaltic pump at about E8 (30). Around E8.25-E9, the heart tube starts to 
loop, the OFT and RV become distinguishable. Upstream the OFT, the future LV is formed at 
the outer curvature of the looped heart (Fig.  3A) (25). At E9, within the atrioventricular canal 
(AVC) and OFT, AV and OFT cushions develop by the accumulation of cardiac jelly. These 
cushions, populated by mesenchymal cells differentiated from endothelial and neural crest 
cells, will eventually form the cardiac valves (i.e. the mitral and tricuspid are derived from 
AV cushions and the aortic and pulmonary valves formed from OFT cushions) (31, 32).  
 
 
Fig.  2. Initial steps in heart formation. 
3D diagrams of heart development with a whole embryo view (upper row) and ventral view of the primitive heart (lower 
row). (A) Cardiac crescent of the primitive heart at E.75. The cardiac crescent is derived from splanchnic mesoderm and it is 
comprised of two pools of cardiac precursors (the first and secondary heart fields (FHF, SHF). The first heart field (FHF) 
contributes to the left ventricle (LV), and the second heart field (SHF) contributes to the right ventricle (RV) and later to the 
outflow tract (OT), sinus venosus (SV), and left and right atria (LA and RA, respectively). (B) Primitive heart tube at E8. 
Fusion of the cardiac crescent at the ventral midline gives rise to the linear heart tube. (C) Looping heart at E8.5 – E9. Here 
the OF and the RV become visible. V = ventricle. (Schemes were taken and modified from (27, 29)). 
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After cardiac looping, around E9.5, trabeculae (myocardial cells covered by endocardial 
layer) emerge developing into the outer curvature of the primitive ventricle, extending villi-
like on the luminal side of the wall. At this stage, the proliferation of endocardial and 
myocardial cells peaks in the developing chambers and in the OFT close to the LV (29) (Fig.  
3B). The trabecular sheets or sponge-like structures are critical for the pumping function of 
the primitive heart. These myocardial protrusions increase cardiac output, allow nutrition and 
oxygen uptake in the embryonic myocardium and separate blood currents in the pre-septation 
heart before vascularization (33). Gradually, remodeling of trabeculae results in the formation 
of papillary muscles, pectinate muscles and is necessary for the formation of the conduction 
system (28, 33, 34). Despite its crucial role in heart chamber maturation, little is known about 
the molecular mechanisms that modulate formation and maturation of the trabeculae. 
Recently, it has been reported that perturbation in the process of trabeculation leads to 
cardiomyopathies such as LVNC (left ventricular non-compaction cardiomyopathy, 
hypertrabecualtion) as well as to cardiac failure, arrhythmias, and thromboembolism (34, 35). 
Therefore, due to its special attention will be given to the morphogenic events occurring 
during the process of heart trabeculation throughout this work.  
 
After the emergence of initial trabecular ridges around E11-13.5, the trabecular sheets grow 
centripetally in the base of the ventricular wall and increase in length towards the lumen. 
Trabecular cardiomyocytes (CMs) are more differentiated than the ones in the compact wall 
(36). The proliferation pattern of CMs at this stage shows high rates on the mural wall and 
distal part of the OFT, and the septum becomes visible (29) (Fig.  3C).The last stage of 
trabecular growth ends with a phase of remodeling (between E14.5-E18.5). This process is 
also known as compaction or consolidation and starts when ventricular septation ends. At this 
stage, trabecular growth stops in luminal direction, it thickens radially and the trabeculae at 
the base regress to the point they cannot be distinguished from the myocardial wall (Fig.  3D). 
The spaces between trabeculae are filled with capillaries as the trabeculae compact.  
 
Trabeculae in the LV are generally thicker and with larger intrabecular spaces that the ones in 
the RV. Furthermore, the trabeculae at the luminal LV merge to produce the anterior and 
posterior papillary muscles of the mitral valve (28). In addition, high proliferation rates are 
found at the base of the trabeculae and high differentiation rates of CMs occur at the luminal 
side (25, 28, 29). This compaction period is completed when a ―mature‖ trabeculated network 
is evident at E14.5 in the mouse heart. The trabecular pattern varies between species and it is 
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considered to be like fingerprints, unique for each individual heart (28). After remodeling-
compaction, the compact layer of the ventricles grows in size mainly by apposition, 
elongating the trabeculae and provoking an outward ventricular expansion. From E14.5 
onwards, the myocardium thickening is accompanied by the invasion of the epicardium 
resulting in coronary vascularization of the myocardial wall. Further growth and compaction 
occur postnatally (28).   
 
It is of relevance to mention other morphological changes that occur during heart chamber 
formation. For example, rotation and septation of the OFT occur around 9.5-10.5 connecting 
the right ventricle to the pulmonary trunk and the left ventricle to the aorta (28). In addition, 
the separation of the aorta and the pulmonary trunk is visible at E12.5-13.5 and it is 
accompanied by an increase in diameter and change in orientation of these great vessels (29). 
It is also around these stages (i.e. E11.5-E13.5) that the messenchymal cells of endocardial 
cushions (AV and OFT cushions) start to proliferate and that ―myocardialization‖ at the 
margin of endocardial cushions occurs. Afterwards, the valve leaflets undergo apoptosis and 
several remodeling steps to finally become fully mature around E16.5 (37). Another important 
region of the heart is the intraventricular septum (iVS). It starts to be formed at E12.5 onward 
and at this stage, it shows high proliferation rate at its bottom and middle areas (29). Finally, 
Sedmera and colleagues emphasized the relevance of atrial trabeculation. Trabeculations in 
the atrium are visible around E12 coinciding with an increase of the atrioventricular pressure 
and therefore help to increase atrial contractility. The remodeling of atrial trabeculae results in 
the pectinate muscles (similar to the papillary muscles in the ventricle), which may improve 
atrial contractility as well (28). 
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Fig.  3. Scheme of mouse heart chamber maturation. 
 (A) Structure and proliferation pattern of the mouse heart at E8.5. At this stage, the tubular heart starts to loop, the OFT, as 
well as primitive ventricles, can be distinguishable and CMs proliferation (Brdu+ cells) is predominant at the ventricles. At 
this stage, the heart is composed only of myocardial cells, cardiac jelly, and endocardial cells. (B) Structure and CMs 
proliferation pattern of the mouse heart at E9.5-10.5. Trabeculae start to emerge from the ventricles wall extending towards 
the lumen and they contain differentiated cardiomyocytes as epicardial cells invade the heart wall. OFT and AV cushions are 
formed. At this stage, there is a high CMs proliferation incidence in the compact zone of the ventricles. (C) Structure and 
CMs proliferation pattern of the mouse heart at E12.5-13.5. Here, the ventricles and atria are already separated; the AVC and 
septum are clearly present. Notice that the trabeculae elongate more towards the lumen and proliferation rates are higher in 
the compact zone of the myocardium. (D) Structure and proliferation pattern of the mouse heart at E14.5-18.5. From E14.5 
onwards, the 4 chamber-heart has formed. The trabeculae start to compact and stop growing. Endothelial cells fill the spaces 
between trabeculae sheets. The great vessels (aorta, pulmonary artery) are formed and the endocardial cushions will be 
converted into cardiac valves.  (Proliferation 3D images were modified from (29) and cell types schemes were modified from 
(25, 31)). 
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1.2.2. Role of apoptosis during heart development 
As described above, the developing heart undergoes several morphological transformations, 
during which cells proliferate, grow and differentiate in a matter of a few days. However, 
these mechanisms alone are not sufficient. It has been reported that cells in the heart as well 
as in other organs have to die trough apoptosis during development in order to sculpt correctly 
each part of the body (2, 3). Without genes of this controlled cell death process, several 
cardiac defects occur. For example, knockout mouse models for apoptosis genes (e.g. caspase 
8, FADD (Fas-associated death domain protein)), and Casper (c-FLIP) develop abnormal 
hearts with aberrant ventricular chambers, with thin and disorganized trabeculae and 
hemorrhage, these mice die around E11 (38). This suggests an important role of apoptotic cell 
death, however, to understand its physiological function it is necessary to have a clear time 
course, localization and cell types of dying cells during different stages of heart development.  
 
For more than 30 years, the chick heart has been the most studied model for cell death due to 
its easy accessibility and manipulation. In 1969, the first evidence of myocardial cell death in 
the embryonic chick ventricle was reported using electron-microscopy (39). These apoptotic 
cells suffered dramatic shape changes, their chromatin condensed, they had a comprised 
cytoplasm, and they started to lose their connections with adjacent cells rounding up to be 
finally expelled from the normal tissue mass into the intracellular spaces of the ventricle. A 
similar study, performed in 1972 by Tomas Pexieder, revealed degenerating cells in the 
bulbular cushions at early stages of development of the chick heart. These dying cells tended 
to be grouped, expelled to tissue boundaries (e.g. epicardio-myocardial, myocardio-
endocardial or even into the lumen), and contained several liposomal vesicles suggesting 
autophagy activity. In addition, there were also neighboring mesenchymal cells in necrotic 
zones acting as macrophages to remove cells (40).  
 
Other studies performed by Michiko Watanabe and colleagues in 1998 and by Katherine 
Schaefer and colleagues in 2004 (41, 42) in the chick embryo heart, confirmed a specific role 
of apoptosis in the shortening of the OFT during heart remodeling. In these studies, cell death 
was identified using more specific histological assays to detect apoptosis such as Terminal 
dUTP Nick End-labeling (TUNEL), Annexin V-biotin, cleaved caspase 3 and the supravital 
lysosomal dye, LysoTracker Red (LTR) (these techniques will be explained in section 1.4). 
Thus, they identified peaks of apoptosis during OFT septation and shortening. It was also 
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shown by co-stainings with markers for CMs (e.i. MF20 and anti-titin) that these specific cells 
die during OFT development.  
 
The avian model has been helpful to confirm that apoptosis is active during the formation of 
the heart. However, until this date, there have been few comprehensive studies that show the 
distribution pattern of apoptotic cells in the developing mouse heart. One of these is the study 
from Sharma and coworkers in 2004 (43). They reported that apoptotic foci are distributed 
throughout different regions of the heart from E10.5 to 13.5. Using TUNEL assay they 
showed that high levels of apoptosis (more than 4%) occur at E12.5-13.5 at the endocardial 
cushions in the AVC and at the OFT. These apoptotic cells presented TUNEL
+
 nuclei with a 
strong signal. Apoptosis in these areas coincides with the strong remodeling, fusion, and 
changes in cellular composition of the endocardial cushions to form the future atrioventricular 
valves. Less intense TUNEL
+
 foci (less than 1%) were observed at the base of the ventricular 
wall and their number peaked at E11.5-12.5 being more abundant at the left ventricle and at 
the intraventricular septum. At the atria, the percentage of apoptotic cells was less than 0.5% 
and it was maintained during development. Sharma and colleagues suggested that apoptosis in 
different cardiac regions can be regulated by different cell death mechanisms and it can be 
associated with the removal of cell populations no longer required for later development, with 
the fusion of the atrioventricular cushions with the atrial septum induced by a probable 
removal of endocardial cells lying next to these structures, and with the separation and 
shortening of structures such as OFT.  
 
The results presented by Sharma are similar to the ones shown by Barbosky and colleagues in 
2006 using the LTR supravital dye, which marks the acidic compartments of the lysosomes. 
They confirmed that the number of apoptotic particles peak at E13-14.5 particularly at the 
OFT and significantly decrease after E15.5. They also showed co-localization of LTR
+
 
particles with markers for cardiomyocytes suggesting a role of cardiomyocyte cell death in the 
remodeling of the OFT (21). Finally, another cardiac region in the embryonic mouse heart, 
where it has been shown that apoptosis is present, is the compact myocardium and in lesser 
extent also in the ventricular trabeculae. Consistent with this, Abdelwahid and colleagues 
determined the apoptosis index based on TUNEL staining at E10.5-15.5 of mouse heart 
development and reported its peak at E12.5 and a significant decrease at E15.5. In addition, 
they reported that apoptotic cell death might be associated with ventricular compaction and 
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differentiation of trabeculae and that it is mediated by the intrinsic (mitochondria) apoptosis 
pathway (44).  
 
1.2.3. Role of apoptosis in congenital heart disease 
As described above, the presence of cell death at different stages of the embryonic heart is 
indicative of a critical role in modulating proper heart formation, together with proliferation 
and differentiation. It has been demonstrated that excessive or diminished apoptosis is present 
in some congenital heart diseases (CHD) (45-49). According to the National Institute of 
Health (NIH), CHD are defects in heart’s structure that very often change the normal blood 
flow through the heart. CHD manifest at birth and their incidence is 8 per 1000 newborns 
(50). It is still not known what the main cause of these defects is and its underlying molecular 
mechanisms remain unidentified. Environmental and genetic factors play an important role 
(51).  
 
It is known that overexpression of the gene LYRM1, which is mainly expressed in adipose 
tissue and in the heart, does not affect cardiomyocyte differentiation, but it inhibits apoptosis 
and increases dramatically cardiomyocyte proliferation (52). This suggests that reduction of 
apoptosis during heart development can be associated with abnormal growth of the embryonic 
heart. For instance, one of the most common disorders of cardiac maturation is the left 
ventricular non-compaction (LVNC) or hypertrabeculation. It is characterized by excessive 
trabeculae growth and it is associated with mutations that cause mitochondrial dysfunction 
leading to abnormal apoptosis (25, 53). Furthermore, inhibition of apoptosis during chick 
heart development causes outflow tract defects similar to those observed in some human 
congenital heart defects (e.g. tetralogy of Fallot, double-outlet right ventricle, transposition of 
the great arteries, among others) (54, 55). Apoptosis can also play a role in pathologies of the 
cardiac conduction system postnatally (45, 47, 48, 56). Apoptotic cells have been found in the 
sinus node, atrioventricular node and His bundle of young human hearts with long QT 
syndrome, arrhythmias or conduction disturbances (48, 57, 58). Similarly, massive apoptosis 
in the right ventricle has been found in biopsy specimens of patients with Uhl’s anomaly and 
arrhythmogenic right ventricular dysplasia (48, 59, 60).  
 
If apoptosis is one of the mechanisms that can lead to CHD, then understanding its regulation 
and its manipulation can serve as alternative therapeutic approaches for these patients. 
Knockout mouse models provide a useful tool to find potential apoptosis checkpoints or 
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signals that trigger abnormal cell death in heart anomalies. Hearts of knockout mice of 
apoptosis genes such as caspase 8, FADD and c-FLIP developed noncompact myoarchitecture 
and impaired cardiomyogenesis (53, 61, 62). In addition, loss of Bax and Bak, pro-apoptotic 
mitochondrial genes, reversed doxorubicin-induced cardiotoxicity damage in neonatal mouse 
hearts (63). This suggests that specific inhibition of apoptosis modulators can improve cardiac 
damage caused by chemotherapy or radiation cancer treatments in young patients. Similarly, 
identification of active apoptosis mechanisms in congenital heart diseases may help to 
develop anti-apoptotic therapies based on stimulation of the IAP (inhibitors of apoptosis) 
family proteins, caspase inhibition, and inhibition of Bcl-2 for these diseases, among others 
(6).  
 
1.3. Different types of PCD  
1.3.1. Apoptosis 
Apoptosis means ―falling off‖ of leaves in Greek and it was coined for the first time by Kerr 
and colleagues in 1972 (64). It is a regulated cell suicide mechanism inherent to the majority, 
if not all, nucleated cells and it is the most extensively studied and well-characterized type of 
programmed cell death (6).  
 
Cells that undergo apoptosis present a series of morphological changes that distinguishes this 
type of cell death from other programmed cell death processes. There are two stages of 
structural changes in apoptotic cells. In the first stage, the nucleus and cytoplasm condensate 
and the cell breaks up into membrane-bound fragments called apoptotic bodies, which contain 
compacted organelles with or without nuclear fragments (Fig.  4). In the second stage, these 
spherical or ovoid bodies are shed from tissue surfaces or are phagocytized by other cells (64, 
65). If the phagocytosis fails, the apoptotic bodies disintegrate and release their content into 
the extracellular space by a process called secondary necrosis (66). Cells undergoing 
secondary necrosis are characterized by clear cytosol and rupture of the cytoplasmic 
membrane with extensive cell disintegration (67). On the contrary, apoptotic cells do not 
release their cellular components, and they are quickly phagocytized (6, 68). 
 
Apoptotic bodies vary in size, they are often found in clusters at intercellular spaces, and they 
can move or disperse from their original site. Since 1972, the difficulty was noted to 
determine the precise duration of the formation and elimination of apoptotic bodies because 
the process appears to start in individual cells of same tissue at different times (64). The entire 
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apoptosis from the initial trigger to cell destruction can take hours or even days (69), however, 
specific biochemical apoptotic changes and removal of apoptotic cells can take less than ten 
minutes (70-72).  
 
 
Fig.  4. Morphological features of apoptosis. 
(A) Scheme of a typical apoptotic cell. (Modified from (65)). 
 
1.3.2. Apoptosis Pathways 
The molecular mechanism of apoptosis has been already elucidated. In 1986, Ellis and 
Horvitz demonstrated that the genes ced-3 and ced-4 are crucial to start apoptosis in the 
nematode C. elegans (73). Cloning studies in Drosophila and C. elegans have identified cell-
death (CED) homologous genes in vertebrates and mammals, such as caspases and some 
mitochondrial genes like Bcl-2, which are conserved through evolution and play a role in the 
initiation or execution of apoptosis (74, 75).  
 
Caspases, a group of cysteine proteases expressed constitutively as inactive precursors in 
almost all cells, are the key players in this cell death machinery and their activation decides 
the final fate of a cell (16, 68). There are two categories of caspases: initiator caspases (e.g., 
casp-8, -9 and -10) and effector caspases (e.g. casp-3,-6 and -7) (Fig.  5). These proteases 
contain an active-site (cysteine), a cleavage site (Asp-X sites) and a protein-protein interaction 
module domain (76). For the caspases to be activated they need to undergo dimerization after 
cleavage by specific upstream enzymes or by self-cleavage due to proximity (68, 77).  
 
There are two main pathways by which apoptosis can be triggered: the intrinsic and extrinsic 
pathway (Fig. 5). The intrinsic pathway gets activated after a stress stimulus such a DNA 
damage which is sensed by damage sensors (e.g. p53), which send signals to turn on the pro-
apoptotic Bcl-2 proteins (e.g. Bax, Bak), which then induce the release of mitochondrial 
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proteins such as cytochrome c (CytC) to the cytosol; CytC forms the apoptosome complex 
together with apoptotic protease-activating factor 1 (Apaf1) and caspase-9 (casp9). Casp-9 
gets activated and it further stimulates executioner casp-3, 6 and/or -7. On the other hand, the 
extrinsic pathway is stimulated by steroid hormones or cytokines such as Fas ligand (FasL) or 
tumor necrosis factor alpha (TNFα), which binds to a death receptor (DR) (e.g. DR4, DR5, 
FasR, and/or TNFR1). Here, casp-8 is recruited by a death receptor and together with other 
molecules (i.e. Fas-associated death domain (FADD)), it forms the death-inducing signaling 
complex (DISC) at the plasma membrane. With this, casp-8 gets activated 8 (cCasp8) by self-
cleaving due to close proximity and it starts the apoptotic cascade; it directly cleaves the 
executioner casp-3, 6 and/or -7 (cCasp-3,6,7) or it can further activate other proteins such as 
Bid that activates Bax and Bak to induce the release of CytC from the mitochondria (76).  
 
 
Fig.  5. Intrinsic and extrinsic apoptosis pathways. 
The extrinsic pathway gets activated when a death receptor ligand (e.g. FasL, TNFα) binds its receptor (e.g. DR4-5, TNFR1 
or FasR), which recruits other proteins to form the DISC complex. The DISC complex is necessary to activate casp-8 that 
furthers activates casp-3. The intrinsic pathway gets activated upon stress stimuli, such as DNA damage caused by radiation, 
toxins or hypoxia. It is sensed by damage sensor proteins such as the tumor protein p53, which activates the pro-apoptotic 
proteins Bax/Bak in the mitochondria, causing the release of cytochrome c (CytC) which forms the apoptosome complex 
together with Apaf-1 and casp-9. In this way casp-9 gets activated and it furthers cleaves casp-3 to continue with the 
apoptosis cascade. Caspase activation is antagonized by inhibitors of apoptosis proteins (IAPs), which themselves are 
inhibited and sequestered by Smac (second mitochondria-derived activator of caspases) or by DIABLO (direct IAP-binding 
protein with low pI). (Modified from (16, 68, 76) using the version 15.1 of the imaging sofware ChemDraw).  
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1.3.3. Necroptosis 
This type of programmed cell death is also known as regulated necrosis, programmed 
necrosis, or necrotic cell death. It depends on the activation of receptor-interacting protein 
kinase-1 and/or 3 (RIPK1, RIPK3) and the phosphorylation of the pseudokinase mixed 
lineage kinase domain-like (MLKL). It is considered to be a back-up or innate mechanism of 
defense against pathogens like certain viruses that can inhibit caspase activation (68, 78). It 
plays a pathophysiological role in diverse disorders such as myocardial infarction, stroke, 
atherosclerosis, ischemia-reperfusion injury, pancreatitis, neurodegenerative pathologies, 
retinal detachment, and inflammatory bowel disease among others (78, 79). Therefore, it is of 
relevance to better understand the molecular pathways of necroptosis in order to find 
therapeutic options to fight these diseases by blocking or inducing this process. For example, 
triggering necroptosis might be an alternative therapy to eradicate apoptosis-resistant cancer 
cells (80). Several studies have shown that certain types of cancer (e.g. colorectal, leukemia 
and multiple myeloma cancer cells) are sensitive to necroptosis inducers such as TNF in 
combination with caspase inhibitors (81, 82). On the other side, inhibition of necroptosis 
might reduce the damage after myocardial infarction in mice. Luedde and colleagues (83) 
showed that the necroptosis complex RIPK1-RIPK3 is formed in the adult heart and that after 
myocardial infarction (MI) the mouse heart overexpresses RIPK3. Moreover, they observed 
that in hearts from RIPK3 knockout mice the effects of MI (e.g. inflammation, reduced 
ejection fraction, hypertrophy and adverse remodeling) were reduced after 30 days post-
infarction, suggesting that inhibition of the RIPK3 protein can be a potential therapy for 
treatment of MI.  
 
Hallmarks of necroptosis are ―balloon-like‖ morphology, lysosomal, mitochondrial and 
plasma membranes rupture and there is cellular leakage, the release of intracellular content, 
and swelling of the cell and organelles. Necroptotic cells also show a translucent cytoplasm 
and condensed chromatin (small and irregular clusters) (66, 78) (Fig. 6).  
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Fig. 6. Morphological features of necroptosis. 
(A) Scheme of a typical necroptotic cell. (Modified from (66) using the version 15.1 of the imaging sofware ChemDraw). 
 
1.3.4. Necroptosis Pathways 
For several years, necrosis was considered as an accidental cell death caused by very strong 
stress or injury. However, it is now well reported that necrosis can be a regulated mechanism 
under certain circumstances (84, 85) (Fig.  7).  
 
First, death stimuli such as DNA damage, viral or bacterial infection and cytokines, are sensed 
by specific death receptors at the membrane of the cell. When inducers such as TNFα or FasL 
bind their death receptors, FADD or TRADD are recruited to form a molecular complex, 
respectively. Casp-8 is also recruited in its inactive form; this is the reason why some scientist 
called this process ―caspase-independent cell death‖. The assembly of these molecules leads 
to the activation of RIPK1, which subsequently phosphorylates RIPK3 (all together form the 
necroptosome complex). RIPK1 can be inhibited by Necrostatin 1 (Nec-1), a potent inhibitor 
that helped to identify RIPK1 activation as a critical step in the necroptosis pathway (86). 
Finally, RIPK3 phosphorylates MLKL resulting in its translocation to the plasma membrane 
leading to membrane rupture. In the case of viral or bacterial infection, the signal is sensed 
either by the DNA-dependent activator of interferon regulatory factor (DAI) or Toll/IL-1 
receptor domain-containing adaptor inducing IFN-β (TRIF), respectively, which in turn 
activates RIPK3 and the further necroptosis cascade. Depending on cell type, lethal trigger 
and polyubiquitination state of RIP1, TNFα-TNFR1 ligation can also lead to the activation of 
the NF-kβ pathway resulting in cell survival (87, 88) by assembling different proteins such as 
TNFR-associated death domain (TRADD),  RIPK1, cellular inhibitors of apoptosis 1 and 2 
(cIAPS) (66, 89). 
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Fig.  7. Molecular pathways of necroptosis. 
The main components of the necroptotic cascade are death receptors that, after triggering, form the necrosome complex that 
involve the activation of RIPK1 and RIPK3 or if the dead stimulus is a viral or pathogen infection it is sensed by damage 
sensor molecules (DAI, TRIF) which phosphorylate RIPK3. RIPK3 the leads to the phosphorylation of MLKL which 
translocates to the plasma membrane to cause cell membrane rupture. If the death stimulus is sensed by the TNFR1 receptor 
in presence of cellular inhibitors of apoptosis (cIAPS) the complex I is formed leading to the activation of the NF-kβ pathway 
resulting in cell survival. (Modified from (66, 78, 79, 89) and created with ChemDraw software version 15.1) 
 
1.3.5. Autophagic Cell Death  
The term autophagy is derived from ancient Greek and means ―self-eating‖ and it was coined 
by the winner of the Nobel Prize in Physiology or Medicine 1972, Christian de Duve (90). In 
the 90s, Yoshinori Ohsumi—awarded with the Nobel Prize in Physiology or Medicine in  
2016—has contributed substantial work in elucidating the molecular machinery and main 
functions of this process (91).  
 
Autophagy is in charge of recycling cell organelles and proteins by lysosomal degradation and 
providing nutrients and energy to cells under starvation conditions in all living organisms 
(92). Furthermore, it is a quality control mechanism that maintains the cellular energetic 
balance under physiological conditions. However, as it is a multi-step regulated process, 
failure can occur at different levels. Defects in autophagy have been linked to different 
pathologies such as cardiomyopathies, myopathies, neurodegenerative disorders, cancer, 
immunological diseases, and metabolic dysfunctions (93).  
 
Autophagy may also lead to cell death under certain conditions. For example, it was reported 
that autophagy mediates physiological cell death during the development of D. melanogaster 
(94) and knockdown of autophagy genes results in abnormal cardiac development in zebrafish 
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and mice (95). In addition, autophagy is responsible for cell death of certain cancer cells 
lacking apoptosis molecules (e.g. Bax, Bak or caspases) in response to cytotoxic agents (96). 
Bax/Bak-deficient cells treated with apoptotic stimuli contain massive cytoplasmic 
vacuolization (8, 97), a main feature of autophagy.  
 
Up to date, it is still not clear which molecular mechanisms and as to how autophagy regulates 
cell death. However, autophagosome formation seems to be required for cells to die after 
starvation, hypoxia, high temperatures, or cytotoxic stimuli when apoptosis cascade is 
inhibited (97). Furthermore, upregulation of autophagy regulators such as Atg5 and Atg6 
leads to cell death, whereas their downregulation results in cell survival (97). This type of cell 
death was named ―autophagic cell death‖ by the NCCD. It is often morphologically 
characterized by the absence of chromatin condensation accompanied by massive autophagic 
vacuolization in the cytoplasm. However, in order to clearly classify cells undergoing 
autophagic cell death, the morphological analysis should be accompanied by the proof that 
autophagy can be suppressed by the inhibition or knocking down of at least two distinct 
autophagic related genes (e.g. Atgs, Beclin 1, or Vps34) (8).   
 
1.4. Apoptosis detection methods 
Programmed cell death research has substantially progressed over the past 15 years. 
According to the NCCD, there are at least 13 programmed cell death modalities (8). In order 
to detect each cell death type, it is critical to combine morphological characteristics with at 
least one biochemical assay. In addition, it has to be proven that the cell death modality does 
not occur when one or more key elements in its molecular pathway are inhibited. In this 
section, the most used and accepted methods to detect apoptosis in vitro and in vivo will be 
discussed. 
 
As it was described in section 1.3, the molecular mechanisms of apoptosis are well studied. 
Therefore, several methods exist to identify this type of cell death. Still, its detection is 
challenging mainly because of the fast and asynchronous speed in which apoptotic cells die 
and disappear. Different cells within tissues are engulfed, shed or dispersed within minutes 
(72). Together with this, it is known that cells in the same tissue, organ or culture die at a 
different frequency or at specific sites, depending on the apoptotic stimuli and cell death 
machinery within each cell type (98). Therefore, the selected tool to detect apoptosis should 
be carefully chosen and optimized according to cell type.  
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Apoptosis has to be assessed at different time points and with at least two different principles. 
The oldest method of identification of apoptotic cells is transmission electron microscopy 
(TEM). Using TEM, one can observe the typical characteristics of the apoptotic cell: intact 
cellular membranes, dark and dense cytoplasm and nucleus, blebs at the cell surface, large 
vacuoles, nuclear fragmentation, and rounded cells expelled from the tissue or neighboring 
cells (99). Watanabe and colleagues mentioned that the advantages of TEM are that very often 
apoptotic cells can be identified even when engulfed in surrounding cells; the cell type 
sometimes can be as well distinguished via specific characteristics such as striated myofibrils 
in the case of cardiomyocytes or skeletal muscle cells (Fig. 8).  
 
 
Fig. 8. Cardiomyocyte undergoing apoptosis in the embryonic chick ventricle. 
This dying cell is located in the intercellular spaces of the developing myocardium. The cell has rounded up, expelled from 
the tissue, and the nuclear chromatin has condensed on one side of the nucleus. The cell was identified as cardiomyocyte by 
the presence of large glycogen pools and scattered myofilaments. This specimen was block stained with uranyl acetate and 
visualized via TEM. (Taken from (39)). 
 
Another well-accepted indicator of apoptosis is DNA fragmentation. This feature occurs late 
in the apoptosis cascade, when the endonucleases are activated and cut the DNA at sites 
between the nucleosomes leaving fragments of similar sizes (e.i. approximately 200 bp). This 
can be evaluated by DNA laddering in an agarose gel or by TUNEL labeling. This technique 
detects the 3’-OH free ends of DNA fragments labeling them via the incorporation of labeled 
nucleotides to strand breaks through the action of terminal deoxynucleotidyl transferase 
(TdT). There are different labels, but the most commonly used are fluorescein labeled 
nucleotides, which can be detected by fluorescence microscopy or flow cytometry. This 
method is broadly used for histological tissue sections analysis (Fig. 9). However it has 
several disadvantages, first, it detects apoptosis in very late stages of the cascade, what means 
that cells which are initiating the apoptosis cascade can be missed leading to underestimation 
of the amount of apoptosis. On the other hand, DNA breaks are not only associated with 
apoptosis, but with DNA damage, in cells with high proliferative or metabolic activity or in 
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necrosis, leading to false positive results (100). For example, high variability (0.2 to 35 
TUNEL
+
 nuclei per 100 cardiomyocytes) in the reported apoptosis levels during end-stage 
heart failure in humans (101, 102) has been observed questioning the accuracy of TUNEL 
staining. In addition, this technique is very expensive and prone to false positive results due to 
sample processing (i.e. tissue sectioning). Therefore, the results obtained by this method have 
to be corroborated by at least one additional apoptosis assay (103).  
 
 
Fig. 9. Apoptotic cells detected in E13.5 mouse embryonic hearts using TUNEL assay and templating technique. 
The template of apoptotic cells summated from ten transverse heart sections from two different E13.5 embryos. TUNEL+ foci 
were found in the interventricular septum (IVS), atrioventricular cushions (arrowhead) and right atrium (white arrow). RA = 
right atrium, LA = left atrium, RV = right ventricle, LV = left ventricle.  (Modified from (43)). 
 
Another principle for apoptosis detection is based on identifying certain biochemical features 
of this cell death mechanism. These can be assessed by searching the activation or change of 
at least one molecule in the apoptosis cascade pathway (Fig.  5). For example, cells that 
undergo apoptosis by the extrinsic pathway can be detected by antibodies that bind to 
activated casp-8, 3, 7, 6 or 9, as well as Bid cleavage and mitochondrial outer membrane 
permeabilization (MOMP) (8). In addition, in order to observe caspase activation over time in 
vitro, there are some available assays based on fluorogenic protease substrates that contain a 
specific cleavage caspase sequence that associates with the cysteine of a fluoromethyl ketone 
(FMK) caspase moiety (6, 99). In this way, when apoptosis is present, this peptide is cut and 
the fluorescent protein released. This can be measured by fluorescence microscopy, flow 
cytometry or fluorescent readers giving the chance to have both, a qualitative and quantitative 
readout. This method works well in living cells, fixed cells, and tissues. However, it has also 
some disadvantages, such as limited permeability in dense tissues and it is also expensive for 
high throughput screenings. In addition, activation of caspases is not only associated with 
apoptosis, but with differentiation, cell proliferation and inflammation (104) leading to false 
positives. In order to confirm the presence of extrinsic apoptosis, it has to be proven that it can 
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be suppressed by pan-caspase inhibitors such as N-benzyloxycarbonyl-Val-Ala-Asp-FMK 
(zVAD-fmk) (8). 
 
On the other hand, cells undergoing apoptosis by the intrinsic pathway is measured by 
changes in mitochondria. Early events in the intrinsic apoptotic pathway occur at the 
mitochondria: inner membrane depolarization, increase in Ca
2+
 concentration, MOMP, the 
release of cytochrome c (cytC) and other pro-apoptotic proteins such as Bid, Bax, and Bak. 
Pro-apoptotic proteins can be detected by antibody staining. To visualize MOMP there are 
different options, one is the transfection of cells with plasmids such as cytC-GFP, AIF-GFP, 
or mitochondrial localization sequences such as MLS-GFP. The cells can be monitored over 
time via fluorescence microscopy (105). In addition, there are some fluorescent dyes such as 
tetramethylrhodamine methylester (TMRM), which accumulates in the mitochondria in 
response to negative membrane potential (99). The advantages of mitochondrial assays are 
that they can be used in vitro, in live cells or in acute slices. The disadvantage is that changes 
in mitochondria also occur in necrosis and other PCD modalities (99, 105). Intrinsic apoptosis 
can be inhibited by zVAD or Bcl-2 overexpression. 
 
Another approach to detect apoptotic cells is by assessing membrane alterations. Apoptotic 
cells externalize phosphatidylserine (PS) from the inside leaflet of its membrane to the outside 
part by the action of scramblase. PS externalization works as a signal for macrophages (99). 
Flipped PS can be detected by Annexin V, a protein that has high affinity to PS in the 
presence of Ca
2+
. There are commercial fluorescent probes tagged to Annexin V to recognize 
apoptotic cells by flow cytometry and fluorescent microscopy. This method detects early 
apoptotic cells before the cell membrane is disrupted and the cell antigens destroyed. This 
allows the identification of cell type, thing that is not possible to assess when late apoptosis 
markers such as TUNEL or vital dyes are used. In spite of its advantages, Annexin V is also 
very expensive to use in a systemic way and in certain cases, it can also recognize necrotic 
cells (Fig. 10). 
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Fig. 10. Detection of alterations in the membrane of apoptotic and necrotic cells using Annexin V-FLUOS. 
Annexin V can detect early apoptosis, advanced apoptosis, and necrosis. Note the morphological differences between the 
roundish apoptotic bodies formed in apoptosis in comparison to the swollen cell debris in necrosis. (Modified from (65))  
 
Apoptotic cells in whole embryos have been broadly visualized by vital dyes, such as acridine 
orange (AO), Nile blue sulfate (NBS), neutral red (NR) or Lysotracker Red (LTR). These 
dyes concentrate in areas of high lysosomal and phagocytic activity. Due to their acidophilic 
nature, they stain acidic compartments (99). However, they cannot distinguish between 
lysosomes degrading apoptotic debris or another type of molecule due to autophagy. 
Therefore, as in the case of almost all described methods, it is critical to use a second 
technique to verify that apoptosis is triggered. Two of the main disadvantages of these dyes 
are the limited tissue penetration and photobleaching. This applies to all dyes with the 
exception of LTR, which has the advantage to penetrate easily into tissues due to its aldehyde-
fixable capacity and in addition it does not fade (Fig. 11). The challenges with this technique 
are that it is limited to temperature, fixation and penetration conditions of the dye, together 
with the fact that it can also stain non-apoptotic cells containing large acidic compartments or 
undergoing autophagy.  
 
 
Fig. 11. Detection of apoptosis in mouse heart development using the supravital dye Lysotracker Red (LTR). 
The bright LTR fluorescent particles mark apoptotic cells in specific areas of the embryonic mouse heart at E13.5. (Modified 
from (21)). 
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Finally, there are some genetically encoded probes for studying the complex progression of 
apoptosis in vivo. These live-imaging tools are mainly based on caspase activity detection (71, 
106, 107) or on the visualization of PS translocation by Annexin V (108). The zebrafish 
(Danio rerio) model is suitable for live fluorescence imaging due to its optical transparency 
during early development (109). Van Ham and colleagues developed a transgenic zebrafish 
that expresses constitutively a secreted human AnnexinV-YFP protein (secA5-YFP), which is 
secreted into the extracellular space. In case the cell undergoes apoptosis, secA5-YFP binds to 
its PS residues on the outer leaflet of the membrane resulting in bright fluorescent signals 
(Fig. 12A-B). With this tool, it was possible to monitor patterns of apoptosis in living 
zebrafish during development and to visualize neural cell death in vivo. These genetic tools 
are very promising to detect cells at different stages of the apoptosis cascade in living 
organisms over time.  
 
Here it is important to highlight the advantages of using genetic tools to monitor apoptosis in 
living contexts. Firstly, in vivo studies offer the possibility to analyze the importance of 
apoptosis in healthy and diseased organisms. Only in the living environment it is possible to 
evaluate the specific time point of appearance, progression and clearance of apoptotic cells, as 
well as their distribution within the tissues and their interaction with other cells, tissues or 
other cell death signaling pathways. From a pathophysiological perspective, Galluzzi and 
colleagues state that researchers should only consider the cell death modalities relevant  to 
affect the embryonic or postnatal development or to be the cause of disease that have been 
shown to occur in vivo (8). Moreover, this complex environment should be aimed at in cell 
death studies to show, if there are other backup mechanisms after inhibition of a specific 
pathway and to show the functional role of specific genes of the pathway that might serve as 
the base to develop strategies to treat diseases. Finally, genetic live-imaging tools allow the 
monitoring of the complex and rapid changes of an individual apoptotic cell or group of cells 
in specific body tissues in real-time before engulfment.  
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Fig. 12. Genetic tool to visualize PS translocation in apoptotic cells by Annexin V. 
 (A) Scheme for the detection of early apoptosis via binding of Annexin V to PS. When apoptosis occurs, PS is translocated 
to the outer leaflet of the cell membrane. Once there, Annexin V binds PS with high affinity and in a calcium-dependent 
manner. Annexin V conjugates are commonly used to detect early apoptosis in vitro and in tissue sections. (B) sA5-YFP 
labels apoptotic cells in live zebrafish embryos (Modified from (108)). Apoptotic cells can be identified as the brightest 
signals in the YFP channel. A5 = Annexin V, s = secretion signal, and YFP = yellow fluorescent protein. 
 
1.5. Aims 
Current methods that detect apoptotic cells are mainly based on evaluating only one time 
point of the apoptosis cascade. As this process is very dynamic and occurs at different times 
in cells of the same tissue the only way to estimate more accurately the rate of apoptosis is to 
monitor them over time. To date, there are some transgenic life-imaging tools available to 
detect apoptotic cells in living organisms such as the transgenic zebrafish expressing Annexin 
V from van Hamm et al. (108) or the SCAT3 mouse from Yamaguchi et al. (107). But 
unfortunately, there is no genetically encoded probe, which has been developed and used to 
track apoptosis in the mouse myocardium. A precise determination of cardiomyocyte 
apoptosis in the developing mouse heart may shed some light on the role of apoptosis in the 
context of physiological heart formation and in the pathogenesis of cardiovascular disease. 
Therefore, the main goal of the present work is to establish a straightforward live reporter-
based method that allows the visualization and quantification of apoptotic cells in the 
embryonic mouse heart in vivo. 
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The proposed system for in vivo visualization of apoptosis is based on earlier work in 
zebrafish (108) with adaptations to the mammalian model. This system expresses a secreted 
human Annexin V (sA5) fused to yellow fluorescent protein (YFP) (Fig. 12). As cells 
undergo apoptosis, sA5-YFP binds with high affinity to its PS residues resulting in bright 
fluorescent signals. The ubiquitous expression will be ensured by the chicken β-actin 
promoter with CMV enhancer element (CAG). The functionality and specificity of the CAG-
sA5-YFP reporter should first be evaluated in stably transfected, undifferentiated and 
differentiated mES cells as well as in vivo in a transgenic mouse model generated from the 
sA5-YFP mES cells. Apoptotic cells labeled by sA5-YFP should be confirmed by co-
stainings with cCasp3 (early apoptosis marker) and TUNEL (late apoptosis marker).  
 
After validating the system, I wanted to focus on the critical question, as to whether apoptosis 
occurs during mouse embryonic development in CAG-sA5-YFP mice. To achieve this goal a 
complete map of the distribution and rates of apoptotic cells and blebs during complete heart 
embryogenesis (E9.5 to P2) needs to be provided, the cell types undergoing apoptosis should 
be identified, the specific localization of the dying cells in the developing heart should be 
described. Additionally and importantly the changes occurring over time of apoptotic cells in 
living embryos and in the beating embryonic heart need to be documented.  
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2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Reagents 
Product Name Company 
Acetic acid Sigma Aldrich, Steinheim, Germany 
Acetic acid Sigma Aldrich, Steinheim, Germany 
Agarose Carl Roth, Karlsruhe, Germany 
Agar Becton Dickinson, Heidelberg, Germany 
Ampicillin Gibco/Life Technologies, Darmstadt, 
Germany 
Calcium Chloride (CaCl2) Sigma-Aldrich, Steinheim, Germany 
Demecolcine Sigma-Aldrich, Steinheim, Germany 
DNaseI (3000 u/ml) Promega, Madison, Wisconsin, Germany 
DNA Gel Loading Dye (6X) Thermo Fisher Scientific, Waltham, MA, 
USA 
dNTP Mix (2.5 mM) Qiagen, Hilden, Germany 
Donkey Serum (DS) Jackson ImmunoResearch, Suffolk, England 
Dulbecco’s Phosphate-buffered saline (DPBS) Invitrogen/Life Technologies, Darmstadt, 
Germany 
Enhancer Solution (5X) Peqlab, Erlangen, Germany 
Ethidium Bromide Fluka/Sigma-Aldrich, Steinheim, Germany 
Ethylenediaminetetraacetic Acid, EDTA Sigma-Aldrich, Steinheim, Germany 
Fetal Calf Serum (FCS)  PromoCell, Heidelberg, Germany 
FLUKA Mounting Medium Fluka/Sigma-Aldrich, Steinheim, Germany 
Gelatin Sigma Aldrich, Taufkirchen, Germany 
Geneticin Sulfate (nmycin, G418) Gibco/Life Technologies, Darmstadt, 
Germany 
Hydrochloric Acid (HCl) Sigma-Aldrich, Steinheim, Germany 
4-Hydroxytamoxifen (4-OHT) Sigma-Aldrich, Steinheim, Germany 
Iscove’s Modified Dulbecco’s Medium 
(IMDM) 
Gibco/Life Technologies, Darmstadt, 
Germany 
Isopropanol VWR, Darmstadt, Germany 
Kanamycin Gibco/Life Technologies, Darmstadt, 
Germany 
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Knockout Dulbecco’s Modified Eagle Medium  
(KO-DMEM) 
Gibco/Invitrogen, Karlsruhe, Germany 
Leukemia Inhibiting Factor (LIF), ESGRO Millipore, Schwalbach, Germany 
L-Glutamine Invitrogen/Life Technologies, Darmstadt, 
Germany 
MasterAmp ―x PCR Premix I (Buffer i) Biozym Scientific, Oldendorf, Germany 
Methanol Merck, Darmstadt, Germany 
β-Mercaptoethanol Sigma-Aldrich, Steinheim, Germany 
2-Methylbutan (Isopentanol) Carl Roth, Karlsruhe, Germany 
3-Morpholinopropanesulfonic Acid (MOPS) Sigma-Aldrich, Taufkirchen, Germany 
Non-Essential Aminoacids (MEM) Gibco/Life Technologies, Darmstadt, 
Germany 
O’GeneRuler 1 kb DNA Ladder, ready-to-use ThermoFisher Scientific, Waltham, MA, 
USA 
Paraformaldehyde (PFA) PanReac AppliChem, Barcelona, Spain 
Penicillin/Streptomycin Gibco/Life Technologies, Darmstadt, 
Germany 
Phosphate-Buffered Saline (PBS) Sigma-Aldrich, Steinheim, Germany 
Potassium Chloride (KCl) Sigma-Aldrich, Steinheim, Germany 
Rat Serum  PAN Biotech, Aidenbach, Germany 
RNA-Loading Buffer New England Biolabs, Frankfurt am Main, 
Germany 
Sodium Acetate Sigma-Aldrich, Steinheim, Germany 
Sodium Citrate Sigma-Aldrich, Steinheim, Germany 
Sodium Chloride (NaCl) Sigma-Aldrich, Steinheim, Germany 
Sucrose Sigma-Aldrich, Steinheim, Germany 
TaqMan Master Mix Applied Biosystems/Life Technologies, 
Darmstadt, Germany 
Taq Polymerase Invitrogen/Life Technologies, Darmstadt, 
Germany 
Tissue-Tek® O.C.T.™ Compound Sakura Finetek Europe B.V., Zoeterwoude, 
Netherlands 
Tris-(Hydroxymethyl)-Aminomethan-
Hydrochlorid (Tris-HCl) 
Sigma-Aldrich, Steinheim, Germany 
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Trypsin/EDTA 0.05% /w/v) 100X Gibco/Life Technologies, Darmstadt, 
Germany 
Tryptone Becton Dickinson, Heidelberg, Germany 
TritonX-100 Sigma Aldrich, Steinheim, Germany 
TRIzol® Reagent Invitrogen/Life Technologies, Darmstadt, 
Germany 
Yeast Extract Becton Dickinson, Heidelberg, Germany 
Z-Val-Ala-As (OMe)-FMK (zVAD-fmk) Abcam, Cambridge, UK 
 
2.1.2. Enzymes 
The following enzymes were purchased from the company Fermentas, Leon-Rot, Germany: 
BamHI, Calf Intestine Alkaline Phosphatase (CIAP), HincII, Klenow Fragment of the DNA-
Polymerase I, NotI, SacII and T4 Ligase. 
 
2.1.3. TaqMan Probes 
The following TaqMan probes were purchased from the company Applied Biosystems/Life 
Technologies located in Darmstadt, Germany:  
Name Reporter 
eGFP FAM-MGB 
TFRC VIC-MGB 
18S rRNA VIC-MGB 
 
2.1.4. Primers  
All primers were designed and ordered to the company Invitrogen/Life Technologies, 
Darmstadt, Germany: 
Name Sequence (5’-3’) 
Sec Signal_Fw 5’ - AGGTTTTGCTGGCACTGTTC - 3’ 
YFP PolyA_Rev 5’ - TGCCGATTTCGGCCTATTGG - 3’ 
YFP_1Fw 5’ - CCGCGTTACATAACTTACGG - 3’ 
CAG_1Fw 5’ - CCGCGTTACATAACTTACGG - 3’ 
CAG_2Fw 5’ - TTCGGCTTCTGGCGTGTGAC - 3’ 
A5_1Fw 5’ - ACCCTCTCGGCTTTATGATG - 3’ 
A5_2Fw 5’ - AGCTCTTCTGCTGCTCTGTG - 3’ 
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2.1.5. Kits 
Name Company 
Annexin V-FITC Apoptosis Detection Kit Calbiochem/Millipore, CA, USA 
EndoFree® Plasmid Maxi Kit Qiagen, Hilden, Germany 
Gentra Puregene Mouse Tail Kit Qiagen, Hilden, Germany 
In Situ Cell Death, fluorescein detection Kit Roche, Mannheim, Germany 
QIAprep Spin Miniprep Kit Qiagen, Hilden, Germany 
QIAquick Gel Extraction Kit Qiagen, Hilden, Germany 
QIAquick® PCR Purification Kit Qiagen, Hilden, Germany 
SuperScript VILO cDNA Synthesis Kit Invitrogen/Life Technologies, Darmstadt, 
Germany 
 
2.1.6. Solutions, Media, and Buffers 
Name Composition 
1x Tris-Acetate-EDTA (TAE Buffer): 20 mM Sodium Acetate 
40 mM Tris (pH 7.6) 
1 mM EDTA 
LB-Medium (1x): 1% Tryptone 
0.5% Yeast Extract (w/v) 
1% Tryptone 
1% NaCl (w/v) 
in deionized water 
LB-Agar-Plates: Prepared as LB-Medium plus: 
1.5% Agar (w/v) 
pour into Petri dishes 
SOB Medium: 2% Tryptone (w/v) 
10 mM NaCl 
0.5% Yeast Extract (w/v) 
2.5 mM KCl 
pH 7.0, autoclave 
10 mM MgCl2 and MgSO4 
MOPS-Buffer: 10 mM EDTA 
200 mM MOPS 
50 mM NaAc 
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Ampicillin: Stock Solution: 100 mg/ml Ampicillin in pure 
water 
Working Solution: 100 μg/ml 
Kanamycin: Stock Solution: 50 mg/ml Ampicillin in pure 
water 
Working Solution: 50 μg/ml 
Sucrose Solution: 20% Sucrose (w/v) in DPBS 
2.5 mM CaCl2 
DPBS Washing Solution: 2.5 mM CaCl2 in DPBS 
PFA Fixing Solution: 2.5 mM CaCl2 in PFA 
Permeabilization Solution: 0.2% (v/v) TritonX-100 in DPBS 
Blocking Solution: 5% (v/v) Donkey Serum (DS) in DPBS 
mESCs culture medium (15% KO-DMEM): 15% FCS (v/v) 
100 U/ml Penicilinin 
100 µg/ml Streptomycin 
0.1 mM MEM 
2 mM L-Glutamin 
0.1 mM β-Mercaptoethanol 
in KO-DMEM 
LIF-Culture Medium: 15% KO-DMEM 
LIF: 1000 - 2000 U/ml 
Differentiation Medium (20% IMDM): 20% FCS (v/v) 
100 U/ml Penicilinin 
100 µg/ml Streptomycin 
0.1 mM MEM 
2 mM L-Glutamin 
0.1 mM β-Mercaptoethanol 
in IMDM 
Freezing Medium: 1:1; 20% DMSO-80% FCS (v/v):15% KO-
DMEM 
Fixing Solution: 3:1; Methanol: Acetic Acid 
1% Gelatin Solution: 100 mg Gelatin 
100 ml PBS 
Hoechst Solution (1 µg/ml): 1 mg/ml Hoechst 33342 in PBS 
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999 ml PBS 
0.01 M Sodium citrate buffer (pH 6.0): 2.94 g  Sodium Citrate 
1000 ml Pure Water 
 pH 6.0 with 1 N HCl 
0.01 M Sodium citrate buffer (pH 6.0): 2.94 g  Sodium citrate 
1000 ml pure water 
pH 6.0 with 1 N HCl 
IMDM and Opti-MEM imaging mediums: 50% rat serum 
1 % Penicillin/Streptomycin 
1% HEPES 
2.5mM CaCl2 
4-OHT tamoxifen:  Stock solution: 12.9 mM in methanol 
Working solution: 40 µM 
zVAD-fmk: Stock solution: 20 mM in DMSO 
Working solution: 50µM  
 
2.1.7. Plasmids 
Name Company 
pBH-UAS-secA5-YFP Provided by Randall T. Peterson, Harvard 
Medical School, Massachusetts, USA 
CAG-Neo3-eGFP CLONTECH Laboratories, Inc., USA 
CAG-sA5-YFP Cloned by Kristel Martinez Lagunas (Section 
3.1) 
  
2.1.8. Equipment and Materials 
Name Company 
Analytical balance XS205 Mettler Toledo, Columbus, OH, USA 
Balance 440-45 KERN, Balingen, Germany  
 
Cell culture dishes (10 cm)   Greiner Bio-One, Frickenhausen, Germany 
Centrifuge 5415D Eppendorf, Wesseling-Berzdorf, Germany 
Centrifuge Multicentrifuge 4KR                                       Heraeus, Hanau, Germany 
Colibri Illumination System  Carl Zeiss, Jena, Germany 
Cryo 1°C Freezing Container Nalgen/Sigma-Aldrich, Steinheim, Germany 
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Cryostat apparatus (Kryotom CM 3050S) Leica, Solms, Germany 
Cryovials Nunc A/S, Roskilde, Denmark 
Falcon 15 ml tubes Falcon, Gräfeling-Lochnam, Germany 
Falcon 50 mL tubes  Falcon, Gräfeling-Lochnam, Germany 
Gel electroporation chambers BioRAD, Munich, Germany 
Gel documentation system   Gel documentation system   
GenePulser cuvettes (0.2 cm) GenePulser cuvettes (0.2 cm) 
GenePulser electroporation system BioRAD, Munich, Germany 
Incubator HERAcell 240 Heraeus, Hanau, Germany 
KOS Microwave HistoStation   Milestone, Sorisole, Italy 
Laser Scanning Microscope Eclipse Ti Nikon instruments, Düsseldorf, Germany 
Macroscope AXIO Zoom V16 Carl Zeiss, Jena, Germany 
Microscope Axiovert40CFL Carl Zeiss, Jena, Germany 
Microscope Axiovert200 Carl Zeiss, Jena, Germany 
Microscope Observer Z1 with Apotome Carl Zeiss, Jena, Germany 
NanoDrop 100 Spectrophotometer Peqlab, Erlangen, Germany 
Pipettor Eppendorf, Wesseling-Berzdorf, Germany 
Rotorgene-qPCR machine Corbett/Qiagen, Hilden, Germany 
Serological pipettes Greiner Bio-One, Frickenhausen, Germany 
Shaker Excella E24 New Brunswick Scientific, Nürtingen, 
Germany 
Slides for tissue sections Menzel-Gläser/VWR, Darmstadt, Germany 
Sterile bank HERAsafe Heraeus, Hanau, Germany 
Stereomikroskop AxioZoom V16 Carl Zeiss, Oberkochen, Germany 
T-flasks - 25 cm
2
 BD Biosciences, Heidelberg, Germany 
Tissue culture dish vacuum gas plasma Falcon, Gräfeling-Lochnam, Germany 
Tissue pen ImmEdge  PEN Vector Laboratories, Burlingame 
Thermocycler  TProfessional TRIO Biometra, Göttingen, Germany 
Thoma counting chamber Marienfeld, Lauda-Königshofen, Germany 
24-well glass bottom plate  In Vitro Scientific, Wien, Austria  
6- and 24-well cell culture plates BD Biosciences, Heidelberg, Germany 
2-well glass bottom chamber Ibidi, Martinsried, Germany 
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2.1.9. Cell lines and biological material 
Name Company 
Mach1™-T1R E.Coli cells Invitrogen/Life Technologies, Darmstadt, 
Germany (ATCC #9637, S. A. Waksman) 
G4 mESCs (SV129;BL/6 background)                              Provided by Nagy Lab, Toronto, Canada 
(110) 
Embryonic Fibroblast (PMEF-NL) (Feeder 
cells) 
Millipore, Schwalbach, Germany 
cDNA EBs derived from R1- CAG-ChR2-
EYFP                
Provided by Tobias Bruegmann, Institute of 
Physiology I, University of Bonn, Germany 
 
2.1.10. Mouse Lines 
Name Company 
CAG-sA5-YFP 
CD1-Tg(CAG-sA5-YFP)KML 
Generated by Dr. Michael Hesse and Patricia 
Freitag from the Institute of Physiology I, 
University of Bonn via diploid aggregation of 
CAG-sA5-YFP Clone 27 (described in 2.5.1) 
 
2.1.11. Primary Antibodies 
Primary Antibody (Isotype, Dilution, 
Temperature, Incubation Time) 
Company 
Anti-Vimentin (Chicken IgGY,  1:800, 
RT, 2h) 
Chemicon, Millipore, Schwalbach, Germany 
Anti-α-Actinin (Mouse IgG1, 1:400, RT, 2h) Sigma-Aldrich, Steinheim, Germany 
Anti-MF20-eFluor® 660 (Mouse IgG2b, 
1:200, RT, 2h) 
eBioscience, Frankfurt am Main, Germany  
 
Anti-α-SMCs (Mouse IgG2b, 1:400, RT, 2h) Sigma-Aldrich, Steinheim, Germany 
Anti-cleaved caspases 3, 7 and 8 (cCasp3-,7-
,8) (Rabbit IgG, 1:50 in tissue and 1:200 in 
mESCs, 4°C, overnight) *Needs Antigen 
Retrieval treatment 
Cell Signaling Technology, Danvers, 
Massachusetts, USA 
 
Anti-eGFP (Goat IgG, 1:50, 4°C, overnight) 
*Needs Antigen Retrieval treatment 
Santa Cruz Biotechnology, Heidelberg, 
Germany 
Anti-PECAM (Rat IgG2a, 1:800, RT, 2h) Becton Dickinson, Heidelberg, Germany 
33 
 
Anti-CD45 (Rat IgG, 1:800, RT, 2h) Chemicon, Millipore, Schwalbach, Germany 
Anti-human Annexin V (Mouse IgG1, 1:50, 
4°C, overnight) *Needs Antigen Retrieval 
treatment 
Abcam, Cambridge, United Kingdom 
 
2.1.12. Secondary antibodies 
All secondary antibodies were ordered from Jackson ImmunoResearch, Suffolk, England: 
Secondary antibody-Fluorochrome (Isotype, Dilution) 
Anti-chicken-Cy5 (Donkey IgGY, 1:400) 
Anti-goat IgG-Cy3 (Donkey IgG, 1:400) 
Anti-mouse-Cy5 (Donkey IgG1, 1:400) 
Anti-rabbit-Cy5 (Donkey IgG, 1:400) 
Anti-rat-Cy5 (Donkey IgG, 1:400) 
 
2.2. Molecular Biology Methods 
2.2.1. Restriction enzyme reaction 
This basic cloning technique was used in several steps (linearization of DNA, cleavage of 
double DNA strands at specific nucleotide sites of target vectors and to identify correct 
product orientation of recombinant DNA) of the cloning strategy to create the CAG-sA5-YFP 
construct. The method uses restriction enzymes also called endonucleases, which are able to 
cut the phosphodiester bonds between nucleotides. There are two types of restriction 
enzymes: blunt end cutters, which cleave double-stranded DNA at the same spot leaving blunt 
ends, and sticky end cutters, which cleave at different spots resulting in 3'- or 5'-overhangs or 
sticky ends (111). The general procedure to carry out the restrictions consisted of the reaction 
mix protocol (Table 1) followed by the Klenow Fragment of the DNA-Polymerase I reaction 
(Table 2) in order to fill-in nucleotides at 5’-overhangs strands to get blunt ends when needed. 
Afterward, the cut DNA plasmid was purified by using the QIAquick® PCR Purification Kit 
(112). If needed, another enzyme cut was run after DNA purification. To finish, before 
ligation it was necessary to remove 5’- or 3’-phosphate groups of the cut vectors by using the 
Calf Intestine Alkaline Phosphatase (CIAP) reaction (Table 3) in order to avoid re-ligation.  
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Table 1. Restriction enzyme reaction protocol 
Component Volume (per 30 µl) 
Buffer (10x) 3 µl 
DNA (5 – 10 µg) x µl 
Enzyme (10 U/µl) 2.5 µl 
Pure water Add up to 30 µl 
Reaction temperature (°C) and time (h) 37 °C, 1 h *Enzyme specific 
Inactivation temperature and time 65 or 80 °C, 20 min *Enzyme specific 
 
Table 2. Nucleotide Fill-in: Klenow Fragment reaction protocol 
Component Volume (per 40 µl) 
Klenow Buffer (10x) 4 µL 
DNA solution 30 µl 
dNTPs (2 mM) 2 µl 
Klenow Fragment (10 U/µl) 2 
Pure water Add up to 40 µl 
Reaction temperature (°C) and time (h) 37 °C, 0.5 h *Enzyme specific 
Inactivation temperature and time 75 °C, 10 min *Enzyme specific 
 
Table 3. CIAP: DNA dephosphorilation protocol 
Component Volume (per 40 µl) 
DNA solution 30 µl 
CIAP (1 U/µL) 1 µL 
Reaction temperature (°C) and time (h) 37 °C, 1 h 
Inactivation temperature and time 85 °C, 15 min 
 
2.2.2. Analysis of DNA fragments by gel electrophoresis 
To evaluate if the desired DNA fragment sizes were obtained after a restriction reaction, a gel 
electrophoresis was run.  This is a basic method to separate nucleic acids or proteins based on 
their size and charge, in which the macromolecules move through an agarose gel under the 
influence of an electrical field (13). Briefly, the DNA samples (approximately 20 µl each) 
were mixed with 4 µl 6x loading buffer and they were loaded on a polymerized 1% agarose-
ethidium bromide (EtBr) gel (1 g agarose in 100 ml of 1x TAE-Buffer and 6 µl EtBr). The gel 
was submerged into a 1x TAE buffer containing chamber and run for 45 min at 90-110 Volts 
(5-8 V per cm of gel). As each DNA nucleotide has a negative charge, the DNA moved 
towards the positive field. The smallest and linear fragments run fastest. Afterward, the gel 
was analyzed under UV light to expose DNA bands tagged with EtBr. In order to identify 
band sizes, 5 µl of a ready to use 1 kb DNA ladder was loaded onto the gel.  
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2.2.3. DNA gel extraction 
This procedure was used to purify the desired DNA fragment bands from an agarose gel. For 
this purpose, the QIAquick Gel Extraction Kit (112) was used. Using this kit different 
impurities (i.e. nucleotides, enzymes, salts, agarose or EtBr) were removed from the DNA to 
get efficient ligation or a reliable sequencing. Briefly, after the restriction reaction, 15 µl of 
DNA solution were loaded on a 1% agarose gel and the gel was run as previously described; 
the desired DNA bands were cut out using a scalpel and they were weighed using an 
analytical balance in grams scale. Generally, 200 mg of gel bands were dissolved in 600 µl of 
QG buffer. Afterward the bind-wash-elute procedure from the kit was followed. Finally, the 
DNA was eluted with 30 µL pure water.  
 
2.2.4. Plasmid Ligation 
A ligation reaction is the formation of a covalent bond between 2 DNA fragments, normally 
the gene of interest and the plasmid vector. This reaction is carried out by the T4 DNA ligase, 
which has the ability to bind both sticky and blunt ended fragments by catalyzing the 
formation of phosphodiester bonds between phosphate and sugar groups of DNA strand (113). 
The ligation reaction consisted of insert, vector, T4 ligase and enzyme buffer containing 
adenosine triphosphate (ATP) that served as a cofactor (Table 4); the reaction was carried out 
at 16°C overnight. Two control ligation reactions were run in parallel: DNA of the vector 
alone with ligase and both DNA, vector, and fragment, but without ligase. The ratio relation 
between insert and vector was calculated with the following formula assuring not to exceed 
300 ng of total DNA using a 3:1 ratio: 
 
                 (  )
   (
                                            (  )
                               
) 
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Table 4. Ligation reaction 
Component Volume (per 20 µl) 
DNA Vector x µl 
DNA Fragment x µl 
T4 Ligase (1 U/µl) 1 µl 
Ligase Buffer (10x) 2 µl 
Pure water Add up to 20 µl 
Reaction temperature (°C) and time (h) 16 °C, overnight 
Inactivation temperature and time 65 °C, 10 min 
 
At the next day, 5 µL of the ligation solution were analyzed via gel electrophoresis to verify 
that the DNA band of the new product was larger than that of the vector alone and of the 
ligation reaction without ligase. Furthermore, approximately one-third of ligation solution was 
used to transform chemical competent bacteria (see method 2.2.5), which later were seeded in 
Kanamycin LB-Agar plates. As in blond-end ligations is likely that the recombinant colonies 
have inserts incorporated in the wrong orientation, the resistant clones had to be further 
analyzed (see method 2.2.6). 
 
2.2.5. Transformation of plasmid DNA in chemical competent Bacteria 
In order to replicate the cloned plasmid DNA, it was introduced into the chemically 
competent Mach1™-T1R E.Coli cells by applying a heat shock. Briefly, 50 µl of Mach1 
bacteria were thawed on ice, then, up to 100 ng of the DNA ligation solution was added and 
incubated for 30 min on ice; in this step, the plasmid was taken up by the bacteria. Afterward, 
the transformed bacteria were exposed to a heat shock at 42°C for 45 s; this served to close 
the bacteria cell’s wall. Next, 250 µL of SOB medium were added followed by an incubation 
at 37°C for 1 h with shaking (400 rpm). After that, they were plated on kanamycin (1:1000)-
containing LB agar plates overnight at 37°C and in this way for selection. For amplification of 
plasmid-DNA, single colonies were picked and were grown in 5 ml kanamycin (1:1000)-LB 
medium at 37°C on a shaker at 220 rpm for 8-16 h.  
 
2.2.6. Isolation of plasmid DNA from bacteria cultures (Miniprep) 
The QIAprep Spin Miniprep Kit was used to isolate plasmid DNA from bacteria cultures at 
small scale. The kit is based on a silica matrix spin-column to which DNA strongly binds in 
the presence of high concentration of chaotropic salts and which can later be eluted using low-
salt buffer. Briefly, 2 ml of bacteria culture were centrifuged for 5 min at 9000 x g at RT 
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followed by binding-washing-eluting steps as stated by the Kits instructions (114). In the final 
step, the isolated DNA pellet was resuspended in 30 µl of pure water. Afterward, the 
recombinant DNA was ready to be analyzed by restriction enzyme digestion and gel 
electrophoresis to verify the inserts correct size and orientation.  
 
2.2.7. Isolation of endotoxin-free plasmid DNA from bacteria cultures (Midiprep) 
Using the EndoFree® Plasmid Purification Kit DNA from bacteria clones containing the 
correct plasmid was amplified and purified to an endotoxin-free grade. This improves 
transfection efficiency as well as avoids unspecific immune responses after application in 
mouse models due to the effect of endotoxins, which are cell membrane components of Gram-
negative bacteria (115). The EndoFree purification protocol is based on a modified alkaline 
lysis procedure, followed by a strong binding of plasmid DNA to a Qiagen anion-exchange 
resin, as well as by washing and eluting steps. The purification was carried out following the 
Kit’s instructions (116).  Shortly, 100 ml of kanamycin-LB medium were inoculated with 100 
µl of previously selected starter bacteria culture, these were incubated at 37°C, at 500 rpm 
overnight and they were centrifuged at 6000 x g for 15 min at 4°C. Afterwards, the lysate 
buffers were added, followed by a washing step to remove endotoxins. Next, the DNA was 
bound to the resin, further washed and eluted. Finally, the purified DNA was resuspended in 
50 µl of the endotoxin-free buffer. Endotoxin-free plasmid DNA was sequenced and later 
transfected into mouse embryonic stem cells (mESCs) (see methods 2.2.8, 2.2.9). 
 
2.2.8. Plasmid DNA sequencing 
The desired plasmid DNA was sequenced by Eurofins MWG Operon (Ebersberg). For 
sequencing 20 µl samples consisting of a mixture of plasmid DNA (100 ng/µl), primers (15 
pmol) and pure water were sent to this company.  
 
2.2.9. Transfection of plasmid DNA in mESCs  
In order to analyze the gene expression of the cloned plasmid, the desired foreign DNA was 
introduced into mESCs by electroporation. This method is based on the use of high-voltage 
electric fields that open temporarily the pores of cell membranes allowing non-polar 
molecules such as foreign DNA to enter the cell (117).  
 
In order to generate a stable transfection, 20 µg of linearized plasmid DNA plus 5 x 10
6
 wild 
type G4 mESCs were used. Briefly, DNA was linearized using a one-site-cutter restriction 
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enzyme. Afterward, G4 mESCs were cultured for two days and were trypsinized at 75% 
confluence (see method 2.3.1). 5 x 10
6
 cells were resuspended in 5 ml of 15% KO-DMEM 
medium and seeded in 10 cm dishes pre-coated with 1% gelatin solution to remove feeder 
cells (inactivated fibroblasts) for 10 min at RT. Later, the medium containing the mESCs was 
collected from the dish, transferred to a 15 ml reaction tube and centrifuged at 5000 rpm for 5 
min. The pellet was resuspended in 800 µl ice cold-PBS containing 20 µg of linearized 
plasmid DNA and transferred into a 2 mm electroporation cuvette. The cell suspension was 
then subjected to an electric pulse of 250 V (Volts), 500 µF (micro Farad) using the 
GenePulser electroporation system from Biorad followed by incubation on ice for 15 min. 
Finally, 2.5 x 10
6 
cells were seeded on 10 cm dishes pre-coated with feeder cells containing 
10 ml of 15% KO-DMEM and 1000 U/ml of LIF to maintain the cells in a non-differentiation 
state. Cells were incubated at 37°C for 24 h followed by media change. After 48 h of 
incubation, the cells were selected with 175 µg/ml Geneticin Sulfate G418 for 8 days. 
Surviving clones expressing the neomycin resistant gene were picked by using a microscope 
and were further expanded.   
 
2.2.10. RNA isolation from mammalian cells 
To be able to analyze the relative expression of the gene of interest in transfected mammalian 
cells, RNA of these cells was isolated using the TRIzol® Reagent protocol under RNase-free 
conditions. This method is based on layers separation. Following the manufacturer 
instructions, 1 ml of Trizol reagent was added to approximately 5 x 10
5
 adherent cells, which 
were homogenized by pipetting up and down 5 times. After addition of chloroform, three 
separate layers formed. The first upper layer was a clear aqueous phase containing the RNA, 
followed by an interphase and a red organic layer containing DNA and proteins. Next, RNA 
was precipitated from the carefully extracted aqueous layer by addition of isopropanol and it 
was centrifuged at 12,000 × g for 10 minutes at 4°C. The RNA pellet was washed with 
ethanol and vortexed for 5 min followed by centrifugation at 7,500 × g for 5 min at 4°C. The 
washed RNA pellet was then resuspended in 50 µl RNase-free water. RNA samples were 
analyzed by agarose gel electrophoresis (1% agarose gel) using 1x MOPS-buffer to verify its 
quality. Approximately 200 ng of RNA were mixed with RNA-Loading buffer; samples were 
loaded and the gel was run at 80 V for 15 min. The RNA integrity was evaluated as intact 
when the 28S and 18S RNA subunits bands were clearly visible, without smearing. 
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2.2.11. Reverse transcription of RNA to cDNA 
In order to be able to measure relative gene expression by real-time quantitative reverse 
transcription PCR (RT-qPCR) (method 2.2.12), it was first necessary to perform a reverse 
transcription from isolated RNA to complementary DNA using a reverse transcriptase (RT). 
For that, the SuperScript VILO cDNA Synthesis Kit was used. A reaction mix for each 
sample was prepared as shown in Table 5. The obtained cDNA was then used as the template 
for the qPCR reaction. 
 
Table 5. Reverse transcription reaction 
Component Volume (per 20 µl) 
Reaction mix (5x) 
(buffer, dNTPs, SuperScript III RT) 
4 µl 
Enzyme mix (10x) 2 µl 
RNA (200 ng) x µl 
RNase-free water  Add up to 20 µl 
Reaction temperature (°C) and time 
(h) 
25°C for 10 min and 
60 min at 60°C 
Inactivation temperature and time 85 °C, 5 min 
 
2.2.12. Relative expression analysis via RT-qPCR 
By using RT-qPCR it was possible to assess the amount of mRNA expressed by transgenic 
cells and to analyze how many copies of the transgenic DNA were integrated into their 
genome. This method measures the increase in fluorescence during the amplification reaction. 
The starting template can be either cDNA or genomic DNA (gDNA) which is labeled by a 
TaqMan probe, which binds specifically to the desired DNA sequence. The probe contains a 
reporter molecule at its 5’ end, a quencher at the 3’ end and gene-specific set of primers. 
Trough FRET (Fluorescence Resonance Energy Transfer) the reporter molecule transfers its 
fluorescence energy to the quencher whenever the probe is intact and they are in a close 
proximity, but when they bind the cDNA strand, they are separated due to the 5’-exonuclease 
activity of the Taq-polymerase and the reporter fluorescence is no longer quenched. This 
fluorescence intensity is directly proportional to the number of PCR product molecules 
(amplicons) generated (118).   
 
In order to detect the relative expression of the YFP transgene, a TaqMan probe against eGFP 
containing the carboxyfluorescein (FAM) reporter was used which was measured in the green 
channel. YFP and eGFP protein sequences only differ in the amino acid Thr-203, a Tyrosine 
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mutation that results in approximately 20 nm shift to longer wavelengths for both the 
excitation and emission spectra (119). Therefore, it was assumed that YFP sequence could be 
detected by an eGFP probe. In order to verify this fact, cDNA of an eYFP expressing cell line 
was used as a positive control. The results were normalized to the housekeeping gene 18S 
rRNA fused to VIC reporter (yellow channel). When copy number analysis was performed, 
the samples were normalized to an endogenous reference gene, known to be present in two 
copies in a diploid genome such as the transferrin receptor gene (TFRC). The qPCR reactions 
were prepared in triplicates as follows (Table 6):  
 
Table 6. qPCR reaction setup 
Component Volume (per 20 µl) 
TaqMan Master Mix (2x) 10 µl 
TaqMan probe (20x)  
Diluted 1:3 
4 µl 
cDNA (~100 ng) or  
gDNA (50 ng/ µl) 
4 µl 
Pure water  2 µl 
 
The samples were pipetted in a 72 sample disc and were run in the Rotorgene-qPCR machine 
using the following two-step qPCR protocol Table 7:    
 
Table 7. qPCR protocol 
Step Temperature Time 
Initial denaturation 95 °C 10 min 
Denaturation 95 °C 10 s 
Primer hybridization 
and  
elongation 
60 °C 45 s 
 4 °C hold 
 
The relative transgene mRNA expression was calculated with the ΔCt-method (120) as 
follows: 
Relative expression = 2
-(Ct of gene of interest (eGFP)-Ct of reference gene (18s sample))
 
 
In order to be able to compare different qPCR runs it was important to always assume the 
same threshold for Cts and to have the same control in each run. The Ct value threshold was 
set to 0.022 in relation to the 18S reference samples in the exponential phase of the qPCR.   
40 cycles 
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2.2.13. Genotyping by PCR 
The polymerase chain reaction (PCR) was used to detect the transgene of interest in the 
genome of transgenic sA5-YFP mice. This method has been described in 1986 by Mullis and 
coworkers (121). Using this method it was possible to amplify specific DNA fragments and 
later to verify them in an agarose gel electrophoresis if the desired fragment size was present. 
The starting template can be gDNA, cDNA or plasmid DNA. Specific oligonucleotide 
primers (Sec Signal_Fw and YFP PolyA_Rev; see sequences at section 2.1.4) were designed 
to bind complementary CAG-sA5-YFP DNA sequences. Primers act as starter strands for the 
amplification. In order to determine the genotype of the generated sA5-YFP mice, 5 mm tail 
tissue samples were taken. From these, gDNA was isolated following the instructions of 
Gentra Puregene Mouse Tail Kit (122). The PCR mix was prepared for each sample as 
indicated in Table 8 and the PCR was run in a Thermocycler using the protocol from Table 9: 
      
Table 8. PCR reaction 
Component Volume (per 20 
µl) 
gDNA (300ng) x µl 
Buffer i (2X)      10 µl 
Enhancer (5X) 4 µl 
dNTPs (10 µM) 1 µl 
Sec Signal_Fw (10 µM) 3 µl 
YFP PolyA_Rev (10 
µM) 
3 µl 
Taq Polymerase                      0.25 µl 
 
Table 9. PCR protocol 
Step Temperature Time 
Initial denaturation      95 °C    4 min 
Denaturation 94 °C 45 s 
Annealing 65 °C 45 s 
Extension 72 °C 1 min 
Final Extension 72 °C 10 min 
 4 °C hold 
 
 
29 cycles 
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2.2.14. Apoptosis induction in sA5-YFP mESCs by 4-Hydroxytamoxifen (4-OHT) and 
DMSO. 
It is known that tamoxifen induces apoptosis in breast cancer cells through the activation of 
both intrinsic and extrinsic apoptosis pathways (123). Its derivative 4-hydroxytamoxifen (4-
OHT) has 50 to 100 fold higher affinity than tamoxifen to estrogen receptors and therefore 
greater potency to induce apoptosis (124). In this work 4-OHT compound was used to induce 
apoptosis in mESCs. It has been reported that a concentration of 40 μM tamoxifen caused the 
highest caspase activity in human hepatocellular carcinoma cells after 4 hours of addition 
(125). Therefore, this concentration of 4-OHT was tested in mESCs and it was concluded that 
it induced cell death after a 3 h incubation based on blebs formation, rounding up of the cells 
and  caspase-3 activation. Thus, this concentration was used in all the in vitro experiments to 
induce apoptosis.  
 
Another reagent used to induce apoptosis in this work was dimethyl sulfoxide (DMSO). It has 
been shown that a concentration of 1% or more DMSO induces apoptosis in a wide variety of 
cells, mainly through the intrinsic pathway (mitochondria) via activation of cCasp9 and 
cCasp3, both in vitro and in vivo (126). Therefore, 1% DMSO was used to assure induction of 
apoptosis in mESCs. 
 
2.3 Cell Culture Methods 
2.3.1. Thawing, Culture and Freezing mESCs 
Transgenic and wild-type G4 mESCs stored in nitrogen tanks were briefly thawed at 37 °C in 
a water bath. In order to avoid cell damage caused by DMSO, which is contained in the 
freezing medium, the cell suspension was resuspended in 5 ml culture medium (15% KO-
DMEM) followed by centrifugation at 1500 x g for 5 min. The pellet was resuspended in 1 ml 
of LIF-culture media (15% KO-DEMEM-1000 U/ml LIF). Approximately 5 x 10
5
 cells were 
seeded in 25 cm
2
 T-flasks containing either 1.3 x 10
6
 feeder cells or coated with 0.1% gelatin 
solution. It was important to double the amount of LIF (2000 U/ml) when the cells were 
seeded on gelatin coated flasks to avoid differentiation.  At the following day, the medium 
was changed.  
 
In order to expand and culture the cells, they were passaged when reaching approximately 
70% confluency (every 2
nd
 or 3
rd
 day). For that, cells were washed with PBS and trypsinized 
with 1 ml of 0.5% Trypsin/EDTA, a proteolytic agent which cleaves proteins chains at the 
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amino acids Arginine or Lysine. The trypsin reaction was stopped with 5 ml culture medium. 
Afterwards, the cell solution was centrifuged at 1500 x g for 5 min and the pellet was 
resuspended in 1 ml LIF culture medium. Cells were counted using a Thoma-cell chamber 
and approximately 150,000 cells were further seeded in 25 cm
2
 flasks with either feeder cells 
or gelatin-coated containing 5 ml of LIF culture medium and incubated at 37°C, 5% CO2 and 
96% humidity. The rest of the cells (0.5 – 1 x 106 cells) were resuspended in 1 ml freezing 
medium (1:1; 20% DMSO (v/v) in Fetal Calf Serum (FCS):15% KO-DMEM) and stored in 
cryovials. The vials were first stored in cryo-chambers containing isopropanol at -80°C, this 
allows to get a slow freezing (- 1°C/h), this avoiding crystal formation due to the DMSO. 
After 2 days, vials were stored in a liquid nitrogen tank.  
 
2.3.2. Differentiation of mESCs: Embryoid Bodies formation 
ESCs maintain their undifferentiated state when they are grown in co-culture with feeder cells 
or in presence of LIF or both, however, when they are cultured in suspension in absence of 
these components, ESCs differentiate spontaneously by forming three-dimensional 
multicellular aggregates called Embryoid Bodies (EBs) (127). EBs are able to differentiate 
into derivatives of all three germ layers (128) giving rise to more specialized cells such as 
cardiomyocytes. The differentiation of transgenic and wild-type mESCs was carried out by 
mass culture also known as a liquid suspension culture (Fig. 13). This method facilitates the 
differentiation of mESCs into cardiomycytes (129). Briefly, approximately mESCs grown in 
feeder cells were trypsinized as described in method 2.2.1. Afterwards, these cells were re-
suspended in 10 ml differentiation medium (20% IMDM without LIF) and seeded in 10 cm 
adherent cell culture dishes to allow feeder cells to attach for 20 min. Afterwards, the feeder 
cells remained attached and the mESCs suspension was transferred to a 15 ml reaction tube to 
determine the number of viable cells. To generate EBs, 2 x 10
6
 mESCs were transferred into 
10 ml of differentiation medium in 10 cm
2
 bacterial-grade (non-adherent) culture dishes and 
incubated at 37°C, 5% CO2 on a horizontal shaker at 70 rpm. This day was defined as day 0 
of differentiation. After 2 days of differentiation, the EB number was determined by 
transferring the EBs solution into a 15ml tube to allow the EBs to sink down for 5 min. Then, 
the medium was aspirated leaving 1 ml medium. The number of EBs was counted from 2 
drops of 5 µl of EBs solution. 750 EBs were seeded in five 10 cm
2
 bacterial-grade culture 
dishes containing 10 ml differentiation medium which were incubated at 37°C, 5% CO2 on a 
horizontal shaker at 70 rpm for 5 more days. After this time, the first medium change was 
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performed. At day 7 of differentiation, the EBs started beating and at day 11 of 
differentiation, they were fixed and further analyzed. 
 
 
Fig. 13. Scheme of ESCs differentiation to embryoid bodies by mass culture. 
Mouse embryonic stem cells (mESCS) were differentiated to embryoid bodies (EBs) using the mass culture or liquid 
suspension protocol. (This scheme was created using and modifying images and clipart from (128, 130)).   
 
2.3.3. Karyotyping of transgenic mESCs clones 
In order to determine the number of chromosomes in the CAG-sA5-YFP mESCs clones, a 
metaphase chromosome spread preparation was performed. For that, mESCs at 70% 
confluency in a 25 cm
2
 flask were incubated for 3 h with 5 ml culture medium and 
Demecolcine (0.1 μg/ml) in order to arrest the cells in metaphase. After this time, the cells 
were trypsinized as in method 2.2.1. Cells were centrifuged and the pellet was resuspended in 
5 ml of 75 mM Calcium-Chloride (KCl) solution followed by 15 min incubation at RT. 
Subsequently, cells were centrifuged for 5 min at 210 x g and the pellet was fixed with 1 ml 
ice-cold fixing solution (3:1; methanol: acetic acid) for 30 min at RT. Then, it was gently 
resuspended and 0.5 ml of the fixed cell suspension were taken with a Pasteur-pipette and 
approximately 100 µl drops were dropped from a height of 50 cm onto slides previously 
washed with ice-cold ethanol. Then, the slides were shortly dried and later they were 
submerged in 1 µg V/ V of Hoechst solution in order to stain the chromosomes. Finally, the 
slides were washed twice with PBS and mounted with mounting medium (FLUKA). At the 
following day, fluorescent pictures of chromosomes were taken using the fluorescent 
microscope Axiovert 200M and the DAPI filter set at 40x magnification. At least 30 spreads 
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were counted for each clone and if more than 70% of the spreads contained 40 chromosomes 
the clone was considered for generation of a transgenic mouse line.  
 
2.3.4. Caspase Inhibition by zVAD-fmk  
In order to inhibit the activity of caspases in the mESCs, the pan-caspase inhibitor zVAD-fmk 
was used. Briefly, 3 x 10
4
 transgenic mESCs per well were seeded in 24 well glass bottom 
plates. When cells were at approximately 70% confluency, 50 µM of zVAD-fmk were added 
2 hours before cell death induction. Cell death was then induced with 1% DMSO. After 24h, 
cells were fixed and stained against cCasp3.  
 
2.3.5. Long-term observation of apoptotic mESCs 
Transgenic and non-transgenic mESCs were grown on gelatin-coated 24-well plates under 
culture conditions described in method 2.2.1. After 2 days in culture and approximately at 
60% confluency, cells were treated with 40 µM 4-OHT for 24 h and non-transgenic cells were 
treated with 1 µM Annexin V-FITC for 30 min at 37°C before tamoxifen addition. Next, 
images were taken with the fluorescence microscope Observer Z1, the Colibri Illumination 
System (blue and white LED), the 20x air-objective, the transmission light and GFP filters at 
37°C and 5% CO2. Using the ZEN 2 Blue Edition Software, a long-term program was set up 
to take serial pictures every 5 min for 24 h.  
 
2.3.6. Fluorescence measurements in mESCs using Image J software 
Transgenic sA5-YFP mESCs either induced or non-induced with 4-OHT for 24 h, were first 
fixed with 4% Paraformaldehyde (PFA) containing 2.5 mM CaCl2 (PFA solution) for 20 min 
at RT, stained for cCasp3 (see method 2.3.1) and imaged using a fluorescence microscope 
(Observer Z1, ZEN 2 Blue Edition Software). Pictures of at least 4-6 areas of 3 different wells 
of transgenic induced, transgenic non-induced and wild-type induced cells were taken. Mean 
fluorescence intensity of each area in the green channel was quantified using the tool 
―Integrated density measurements‖ from the image analysis software ―Image J‖, version 
1.37A. Sample's total fluorescence was calculated by deducting sample's fluorescence from 
background's fluorescence. 2 different experiments were run and statistical analysis (Student’s 
t-test) was performed.  
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2.4 Immunohistochemistry Methods 
2.4.1. Immunostainings in mESCs 
Transgenic and non-transgenic mESCs were shortly washed with a washing solution and 
fixed at RT with fixing solution for 30 min. The addition of calcium to all solutions and 
mediums was important to ensure the binding of Annexin V to PS when apoptosis induction 
experiments were carried out.  After fixation, the fixing solution was removed and cells were 
washed two times with DPBS. For the immunostainings, cells were permeabilized at RT with 
permeabilization solution for 10 min. In order to avoid unspecific staining, cells were blocked 
at RT with blocking solution for 20 min. After a quick washing step with DPBS, primary 
antibodies (see dilutions in section 2.1.11) were diluted in blocking solution and added to the 
cells. Afterwards, cells were incubated at 4°C overnight or 2 h at RT, depending on the 
antibody (specified in section 2.1.11). After three washing steps with DPBS, cells were 
incubated at RT for 1h with specific secondary antibodies (see dilutions in section 2.1.12), 
which were diluted in Hoechst solution. The cells were shortly washed with washing solution, 
mounted with 1 drop of mounting medium and coverslips, stored at RT to let them dry 
overnight and stored at 4°C in darkness until their analysis. 
 
2.4.2 Immunostainings in EBs and embryonic tissue sections 
Transgenic and non-transgenic EBs, embryos and embryonic hearts were fixed overnight in 
fixing solution. Then they were washed twice with washing solution followed by incubation at 
4°C in sucrose solution overnight. Tissue was frozen in Tissue-TEK O.C.T compound using 
isopentanol and dried ice. Afterward, 10 µm tissue sections were cut with a Cryostat device. 
For some antibodies (specified in section 2.1.11) it was necessary to perform antigen retrieval 
(AR) (high-temperature heating treatment) to be able to disrupt cross-links between formalin 
and protein enabling epitope detection. It is known that formalin fixation causes protein's 
structure modifications hiding antigen sites (131). Therefore, sections were pre-treated with 
0.01 M sodium citrate buffer (pH 6.0) for 15 min at 93°C using a Microwave HistoStation. 
After heating, sections were allowed to cool at RT for 15 min. After AR the native YFP signal 
was lost, therefore it was necessary to stain the tissue against YFP together with the other 
primary antibodies. After AR, tissue sections were permeabilized, blocked, stained, mounted 
and stored in the same way as described in section 2.4.1.  
 
For the detection of late apoptotic cells, the In Situ Cell Death, fluorescein Detection Kit from 
Roche was used. This method is based on the detection of DNA strand breaks by labeling of 
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free 3’-OH termini using the terminal deoxynucleotidyl transferase (TdT), which catalyzes 
polymerization of labeled nucleotides to free 3’-OH ends (TUNEL reaction). Briefly, TUNEL 
positive (sections treated with 3000 u/ml DNaseI for 5 min at RT) and negative controls 
(sections incubated with Kit´s Labeling solution) were prepared.  Later, sample sections were 
washed twice with DPBS and they were treated with the Kits' TUNEL reaction mix followed 
by incubation for 1h at 37°C in a humidified space. Finally, slides were quickly washed with 
DPBS and mounted. The detection of apoptotic cells was analyzed under a fluorescence 
microscope using FITC and Cy3 filter sets.  
 
2.5. Animal experiments 
2.5.1. Generation of the CAG-sA5-YFP mouse line 
The transgenic CAG-sA5-YFP mouse line, which official name is CD1-Tg(CAG-sA5-
YFP)KML according to the International Committee on Standardized Genetic Nomenclature 
for Mice, was generated from the CAG-sA5-YFP mESCs line by complementation assays 
with diploid embryos from wild-type CD1 mice (132) (the aggregation was kindly performed 
by Dr. Michael Hesse and Patricia Freitag from the Institute of Physiology I, University of 
Bonn).  
 
Briefly, 3 days before aggregation, clones 27 and 28 from the CAG-sA5-YFP mESCs were 
thawed and cultured 25 cm
2
 flasks with feeder cells as described in method 2.2.1. At the 
following day, the medium was changed. When the cells were at ~70% confluency they were 
trypsinized the same way as performing a passage. After stopping the trypsin reaction with 
medium, approximately 10 ml of the cell suspension were left for 10 min in a 0.1% gelatin 
coated 6 cm
2
 cell culture dish to remove feeder cells. Afterwards, different dilutions (1:12.5, 
1:25, 1: 50, 1:100 and 1:200) of the mESCs were prepared in culture medium containing 2000 
U/ml LIF. These were then seeded on 0.1% gelatin coated 6 cm
2
 culture dishes containing 6 
ml LIF-culture medium. Cells were incubated at 37°C and 5% for 24 h on the day before 
aggregation. For aggregation with diploid embryos, the protocol described by Takanaka and 
coworkers was followed in which clumps of approximately 6 -10 ESCs were aggregated with 
previously prepared zona pellucida-free embryos flushed from oviducts 2.5 days post coitum 
(dpc) from pregnant mice. One day after aggregation, embryos in blastocyst stage (3.5 dpc) 
were transferred to pseudopregnant CD1 recipient females. After approximately one month, 
the first germline transmission chimera embryos were analyzed under fluorescence 
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macroscope to make the first evaluation of YFP expression. Afterward, chimera offspring was 
genotype and analyzed by PCR (method 2.1.13.).  
 
2.5.2. Isolation of mouse embryos and embryonic hearts 
Embryos at different embryonic stage (E9.5 - P2) were taken out from pregnant mice at the 
respective day. The day of embryonic development was determined by counting the day of the 
vaginal plug as day 0.5. The pregnant mice were killed by cervical dislocation and the 
embryos were dissected and then placed in ice-cold PBS containing CaCl2. The placenta and 
in some cases also the yolk sac were removed. As fast as possible, embryos were scanned 
under a fluorescent macroscope to distinguish transgenic and wild-type embryos. Immediately 
after, embryos were fixed in fixing solution for 2-4 h; they were quickly washed and 
incubated in sucrose solution for 24 h.  
 
For the isolation of embryonic hearts (E11.5-P2), embryos' head was removed, the thorax was 
opened and the heart was taken out with small forceps. All connective tissue was removed 
and hearts were then fixed in the same way as the isolated embryos.  
 
2.6. Preparation, ex-vivo culture and live imaging of A5-YFP embryos and hearts at 
E8.75-9.5  
Pregnant mice were killed by cervical dislocation at day 8.75 - 9.5 postcoitum. The uterus was 
dissected and immersed in 37°C warm IMDM or Opti-MEM culture medium and embryos 
removed from the uterus and yolk sac under a stereomicroscope. Embryos were scanned 
under a fluorescent microscope to select for sA5-YFP expression and heart beating. 
Approximately 500 µl of 2% low-melting agarose were poured into an imaging chamber with 
glass bottom. Holes were dug into the agarose before embryo dissection. Selected embryos 
were placed in the agarose holes and the imaging chamber was filled with IMDM imaging 
medium. These culture conditions were used to document massive apoptosis in E8.75 
embryos as a proof of concept of the system. Later, I change the following culture conditions: 
embryos were immersed directly in liquid 2% low-melting agarose and hold into the desired 
position until the agarose polymerized. The chamber was filled with Opti-MEM imaging 
medium. For the live imaging, the chamber was positioned into an inverted confocal 
microscope live imaging system and incubated at 37°C and 5% CO2. Whole body or the heart 
of transgenic sA5-FYP embryos was imaged for 15 to 20 h. Pictures were taken every 5 - 10 
min using a 10x air objective. YFP was excited by a 515 ± 30 nm laser (8-15% power) and a 
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595 ± 50 nm laser (8-15% power) was used to excite autofluorescence. The transmission light 
source was simultaneously used. Z-stack slices depth was defined between 4-6 µm, depending 
on the experiment (Fig. 14).  
 
 
Fig. 14. Scheme of the live-imaging setup for monitoring apoptosis in sA5-YFP embryos. 
sA5-YFP embryos were isolated and imaged using the depicted imaging set up. (This scheme was created using and 
modifying images and clipart from (130, 133-136) ).  Fluorescent images of E8.5-9.5 sA5-YFP embryos were generated in 
this work.  
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3. RESULTS 
3.1. Generation of a CAG-sA5-YFP expression cassette 
As mentioned in section 1.5, the main goal of this PhD thesis is to generate a straightforward 
genetic tool for the identification of apoptotic cells in the developing mouse heart in vivo. For 
that, the first step was to create via molecular cloning the desired plasmid cassette that 
contains the ubiquitous promoter, CAG, and our gene of interest, sA5-YFP (see Fig. 15). The 
CAG (chicken β-actin promoter with CMV enhancer) promoter has been proven to drive 
expression of transgenes in all types of mammalian cells, with predominant expression in 
muscle cells during all stages of development (137-140).  
 
The CAG-sA5-YFP construct (6995bp) was generated using the pBH-UAS-secA5-YFP 
vector (provided by Randall T. Peterson, Harvard Medical School, Massachusetts, USA) and 
the CAG-Neo3-eGFP (CLONTECH Laboratories, Inc.) vector. The first vector was cut with 
the restriction enzyme SacII, its ends were modified with Klenow-Fragment leaving a blunt 
end and it was further cut with BamHI. The vector was then analyzed by gel electrophoresis. 
Three DNA fragments (3692, 3569 and 1892 bp) were obtained. The 1892 bp fragment was 
removed from the gel and it was ligated to the 5109 bp fragment obtained by cutting the 
CAG-Neo3-eGFP vector with the restriction enzymes NotI and BamH1. The ligation resulted 
in a 6995 bp product named CAG-sA5-YFP (Fig. 15A). Afterward, this plasmid was 
transformed into chemical competent MACH-1 E.coli cells and clones were selected on LB-
Agar plates with Ampicillin. On the following day, 6 resistant clones were isolated and 
amplified in LB suspension culture. The correct orientation of the CAG-sA5-YFP construct 
was verified by cutting the plasmid with the restriction enzyme HincII. Four clones out of six 
showed the expected band sizes, 5267 bp and 1732 bp (Fig. 15B). DNA of clone number 2 
was sequenced using the following primers: CAG_1Fw, CAG_2Fw, A5_1Fw, A5_2Fw, and 
YFP_1Fw (see 2.1.4.). The expected nucleotide sequence was confirmed by sequencing 
(Method 2.2.8.). Finally, DNA of clone number 2 was purified in an endotoxin-free 
preparation and linearized with the enzyme Alw44I for it to be introduced in mammalian cells 
as explained in the following section.  
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Fig. 15. Generation of the CAG-sA5-YFP expression cassette. 
(A). Scheme of the cloning strategy for the generation of the CAG-sA5-YFP plasmid. (B) Gel electrophoresis of DNA 
samples of bacteria transformed clones cut with the restriction enzyme HincII. The expected fragment sizes with correct 
orientation are 5267bp and 1737bp. Positive clones are marked with white arrows. 
 
3.2. Apoptosis detection in sA5-YFP transgenic mESCs as a proof of principle. 
Once the CAG-sA5-YFP construct was successfully cloned and sequenced, it was tested in 
vitro with the purpose to evaluate its functionality as an apoptosis marker. For that, transgenic 
mESCs stably expressing sA5-YFP were generated by electroporation (Method 2.2.9). After 8 
days of neomycin selection, approximately 46 clones were picked under fluorescence light to 
detect YFP expression. From these, 3 clones (27, 37 and 38) displayed a stable YFP 
expression (Fig. 16A-B). As explained in section 3.1, the CAG promoter drives the expression 
of sA5-YFP ubiquitously. Thus, this expression was defined as ―background-ubiquitous 
expression‖, which was darker than that of apoptotic cells (bright sA5-YFP signal). In 
addition, the YFP expression level was analyzed by qPCR. Relative YFP expression level of 
clone #27 was comparable to that of a control mESC line stably expressing EYFP under the 
control of the CAG promoter (RNA sample kindly donated by my colleague Tobias 
Bruegmann (141). As part of clone characterization and to be able to use it later to generate 
transgenic mice, the newly generated mESCs lines were karyotyped (Method 2.3.3.). All three 
clones contained 40 chromosomes in more than 70% of the counted spreads corresponding to 
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a normal karyotype (Fig. 16C). Therefore, they were considered to have a high chance to 
contribute to the germline. 
 
Next, the system was tested upon apoptosis stimuli using 4-Hydroxytamoxifen (4-OHT) at 40 
µM, as a proof of concept. This concentration was chosen based on the report of Riss and 
Moravec (125) (Method 2.2.14). Within 24 hours after apoptosis induction, bright YFP-
fluorescence signals could be observed due to accumulation of sA5-YFP at flipped PS 
residues in the membrane of apoptotic cells (Fig. 12). In order to corroborate that apoptosis 
was induced 24h after 4-OHT addition cells were fixed and stained against cCasp3, an early 
marker of apoptosis. YFP
+
 and cCasp3
+
 fluorescence signals increased after apoptosis 
induction. Labeled cells became roundish and detached from the bottom of the culture wells 
showing the typical apoptosis morphology (Fig. 16D). In addition, fluorescence 
measurements were performed via image software analysis (Image J, Version 1.37 A). A 
significant increase in YFP-fluorescence intensity over time of two independent experiments 
was observed, confirming the accumulation of YFP at the membrane of apoptotic cells (Fig. 
16E).  
 
In addition, as apoptosis is a very dynamic process (142), it was of interest to track apoptotic 
cells over time using this transgenic system. To do so, long term observation experiments 
were run (Method 2.3.5). Briefly, transgenic sA5-YFP and non-transgenic G4-mESC cells 
were grown on 1% gelatin coated plates and when they reached 60-80% confluency, 
apoptosis was induced with 4-OHT at 40 µM. As a control and to validate the efficacy of the 
sA5-YFP system against a commercial Annexin V probe, wild type mESCs were incubated 
with 1 µM Annexin V-FITC for 30 min at 37°C before apoptosis induction. Afterwards, time-
lapse images were taken every 5 min for 24 hours using the Axiovision Observer Z1 
fluorescence microscope. During the first 6 hours it was possible to detect apoptotic cells 
emerged from mESCs colonies. After approximately 50 min the first sA5-YFP labeled cells 
were detected and it was possible to observe a dot-like formation of blebs 175 and 275 
minutes after induction (Fig. 17, upper row). These cells were comparable in morphology to 
the ones marked by a commercial Annexin V-FITC probe (Fig. 17, lower row). Examples of 
rounded cells and blebs are marked with white arrows. From these results, it could be 
concluded that the sA5-YFP transgenic system is able to detect apoptotic cells in a way 
comparable to commercially available Annexin V probes.  
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Fig. 16. Apoptosis detection in A5-YFP transgenic mESCs. 
 (A) Transgenic mESCs stably expressing sA5-YFP. Note the ―background-ubiquitous‖ YFP expression (white arrow) and 
the few bright YFP+ cells (white square). (B) Relative expression levels of sA5-YFP in a stable expressing mESCs clone 
compared to wild type G4 mESCs and mESCs expressing YFP. (C) Normal karyogram of the transgenic mESCs clone 27. 
(D) Fluorescent images revealing the accumulation of sA5-YFP in the membrane of apoptotic cells and co-localization of 
YFP+ (green) and cCasp3+ (purple) signals after apoptosis induction. (E) Quantitation of sA5-YFP fluorescence signals from 
(D) over time. Fluorescence intensity of YFP significantly increased 24 h after apoptosis induction by 4-OHT addition. G4 (-) 
= G4 mESC line, YFP (+) = mESC line expressing EYFP, 4-OHT = 4-hydroxytamoxifen, TL = transmission light, eGFP = 
enhanced green fluorescent protein, Afl = autofluorescence, cCasp3 = cleaved caspase 3. Data are shown as mean ± s.e.m., n 
=2, *** = P < 0.001 (Student's t-test). Bars are 50 µm (A, D) and 5 µm (C).  
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Fig. 17. Long term observation of apoptotic cells in sA5-YFP and control mESCs. 
Time course of apoptotic cells in transgenic sA5-YFP (upper row) and non-transgenic mESCs (lower row) upon apoptosis 
induction. Transgenic sA5-YFP mESCs were treated with 4-OHT at 40 µM for 24 hours. Wild type mESCs were pre-
incubated for 30 min with 1 µM of commercially available Annexin V-FITC before 4-OHT addition. Time-lapse images 
were recorded every 5 min. Examples of apoptotic cells labeled by sA5-YFP or Annexin V-FITC are shown by white arrows. 
Bar is 20 µm.  
 
3.3. sA5-YFP marks apoptotic cells in differentiated cells 
Transgenic mESCs stably expressing sA5-YFP were differentiated to embryoid bodies (EBs) 
(Fig. 13). EBs are 3-dimensional cell aggregates consisting of all three germ layers (i.e. 
endoderm, ectoderm, and mesoderm). They recapitulate early stages of mammalian 
development. EBs, cultured in suspension for 8 - 15 days, form structures homologous to the 
visceral yolk sac (mesoderm and endoderm) of post-implantation embryos (143). It is well 
known that apoptosis takes place during development (107, 144) and that massive cell death is 
present during EBs formation at the periphery and in the center of the body due to cavitation 
(145). Therefore, EBs are a good model to test and validate the sA5-YFP system in a more 
physiological environment in which apoptosis occurs. 
 
For this purpose, EBs at day 11 of differentiation were fixed, sectioned and co-stained with 
cCasp3 (early apoptosis marker) and TUNEL (late apoptosis marker) (Fig. 18B-E). Bright 
YFP
+
 signals were present at the periphery and in the center of the EBs in the same regions 
where cCasp3
+
 and TUNEL
+
 events were found. Quantitation revealed approximately 1.7 ± 
0.48% cCasp3
+
, 1.5 ± 0.26% sA5-YFP
+
 and 3 ± 0.5% TUNEL
+ 
signals of total nuclei in the 
analyzed EBs. As mentioned before, the YFP positive signals followed the same pattern as the 
two apoptosis markers; however, it was observed that 30 ± 2.5% 
 
of the cCasp3
+ 
signals co-
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localized with sA5-YFP
+
, whereas only 13 ± 3.8 % of the TUNEL
+ 
signals co-localize with 
sA5-YFP
+
 (Fig. 18F-G). 
 
These results could indicate low specificity of the sA5-YFP system, as more than 50% of the 
signals do not co-localize with cCasp3 and TUNEL markers. However, based on the typical 
morphological and biochemical changes of the apoptosis cascade, it is known that the 
apoptotic cells show a very clear membrane ring-like morphology at the early stages of 
apoptosis and then start to form blebs. These blebs contain cellular components to avoid their 
release to the extracellular space which would cause inflammation (8). Thus, as caspase 
activation occurs in the cytoplasm, some membrane sA5-YFP
+
 blebs will contain caspase 
residues. In addition, it is known that caspase 3 activation is initiated in the cytosol and later 
translocates to the nucleus. Moreover, caspase 3 activation is transient and reaches in less than 
10 min its maximal activation (71). On the other side, TUNEL marks nuclei of cells in a late 
apoptotic state, meaning that the early apoptotic cells should not contain fragmented nuclei. 
Therefore, this is the first indication that the sA5-YFP transgenic system might detect cells at 
different stages of apoptosis (early-intermediate-late).  
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Fig. 18. Detection of apoptotic cells in differentiated mESCs. 
(A) Transgenic EBs at d11 of differentiation derived from mESCs stably expressing sA5-YFP. (B, C) Frozen section of a 
transgenic sA5-YFP EB co-stained against cCasp3 and TUNEL stained, respectively. (D, E) Magnification of the area 
marked by a white box in (B and C) showing apoptotic bodies with co-localization of YFP+ signals and cCasp3+ or TUNEL+ 
(white arrows). Note membrane ring-like sA5-YFP signals (white star) and membrane blebs (white circle). (F) Quantitation 
of early (eGFP+ and cCasp3+) and late apoptosis (TUNEL+) rates in transgenic EBs at d11 of differentiation. (G) Percentage 
of co-localization of GFP+ with total cCasp3+ or total TUNEL+ signals. Data are shown as mean ± s.e.m. **P < 0.01 
(Student's t-test), n=4. BF = bright field, Afl = autofluorescence, HOECHST = nuclear staining, cCasp3 = cleaved caspase 3, 
TUNEL = Terminal deoxynucleotidyl transferase dUTP nick end labeling and sA5-YFP = secreted Annexin V-yellow 
fluorescent protein. *Sections were stained with eGFP antibody after antigen retrieval treatment to detect the YFP signal. 
Bars are 200 µm (A), 100 µm (B, C) and 10 µm (D, E). 
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3.4. Detection of apoptotic cells by sA5-YFP is independent of caspase activation 
Apoptosis is not the only programmed cell death process, as cells can still die even in the 
presence of caspase inhibitors (79, 146). Necroptosis has been described as programmed 
necrosis, in which the caspase activation cascade is inhibited and a specific molecular 
pathway is activated. Therefore, it was of interest to test if the sA5-YFP transgenic system 
depends exclusively on caspase activation to detect dying cells. For this purpose, I cultured 
transgenic sA5-YFP mESCs in the presence or absence of zVAD-fmk, a widely used pan-
caspase inhibitor (147, 148). After 2 h of caspase inhibition with 50 µM of zVAD-fmk, I 
added 1% DMSO to induce cell death for 24 h (Method 2.3.4). After this time, I fixed and 
stained the cells for cCasp3 (Method 2.4.1). I observed that cleaved Caspase 3 was 
significantly reduced in cells treated with zVAD-fmk (Fig.  19). Furthermore, I could also 
notice that sA5-YFP marks dead cells even if cCasp3 is not active. These bright sA5-YFP
+
 
cells had a condensed nucleus and sA5-YFP accumulation in the membrane, which occur in 
both apoptotic and necroptotic cells. This indicates that the sA5-YFP transgenic system is 
independent of caspase activation and it might be capable of detecting other types of 
programmed cell death such as necroptosis. 
 
 
 
Fig.  19. Inhibition of caspase activity in sA5-YFP mESCs. 
Transgenic sA5-YFP mESCs were incubated with the pan caspase inhibitor (zVAD-fmk) at 50 µM 2 h before cell death 
induction. Cell death was induced with 1 % DMSO. After 24 h, cells were fixed and stained against cCasp3. Casp-3 activity 
was clearly inhibited and bright YFP+ signals could still be observed after inhibition. This indicates that sA5-YFP cell death 
reporter is caspase independent and it may detect other types of programmed cell death such as necroptosis. Bar is 20 µm, 
n=3. 
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3.5. sA5-YFP marks apoptotic cells during mouse embryonic development 
In order to understand the dynamics of apoptosis and to be able to visualize and observe 
apoptotic cells in living animals, the sA5-YFP transgenic system was tested in vivo. For that, 
a transgenic mouse line was generated from the CAG-sA5-YFP mESC line by 
complementation assays with diploid embryos as described in section 2.5.1 (the aggregation 
was kindly performed by Dr. Michael Hesse and Patricia Freitag from the Institute of 
Physiology I, University of Bonn).  
 
As a proof of concept and because apoptosis is known to occur during embryonic 
development (107), 8.5 days old chimeric embryos of the first transgenic litter were dissected 
and scanned under fluorescence macroscopy for bright YFP signals, such as those described 
in the zebrafish sA5-YFP transgenic model (Fig. 12B). Small and roundish bright YFP 
particles within the heart and the yolk sac could be identified in the isolated embryos (Fig. 
20).  
 
 
Fig. 20. Macroscopic pictures of sA5-YFP chimeric and transgenic embryos. 
(A, B) Chimeric embryos at day 8.5 and (C, D) transgenic embryos at E9.5 expressing sA5-YFP are shown. Bright green 
fluorescent signals (white arrows) show typical apoptotic features: accumulation of sA5-YFP in the outer layer of the 
membrane and roundish morphology. sA5-YFP = secreted Annexin V-yellow fluorescent protein, Afl = autofluorescence.  
Bars are 200 µm (A, B and C) and 500 µm (D).  
59 
 
To evaluate if those small particles were apoptotic cells, transgenic embryos at E9.5-10.5 and 
hearts from transgenic embryos at E10.5 were dissected and analyzed by fluorescence 
macroscopy and immunostainings. Macroscopic pictures revealed very bright YFP
+
 signals in 
embryos within the yolk sac, otic placode, hind brain and heart (Fig.  21A-E), as reported 
earlier (107, 144). Additionally, co-stainings with cCasp3 and TUNEL staining were 
performed in frozen sections of transgenic E9.5 embryos (Fig. 22A-D). Co-localization of 
YFP
+
 signals with cCasp3
+
 was observed within the otic placode, in the neural tube, and in 
the heart. In addition, it was observed that these positive cells also exhibited nuclear 
condensation (a hallmark of apoptosis), as shown by Hoechst counterstaining. However, it 
was also noted that few of the sA5-YFP
+
 signals co-localized with TUNEL positive cells 
suggesting that this reporter system mostly detects cells in early/intermediate stages of 
apoptosis. 
 
 
Fig.  21. Apoptosis detection in sA5-YFP mouse embryos. 
(A, E) Macroscopic pictures of transgenic embryos at E9.5, 10.5 and a transgenic heart at E10.5 expressing sA5-YFP. Bright 
green fluorescent signals (white arrows) label apoptotic cells during embryonic development within the otic ring, the neural 
tube and the heart. These signals can be distinguished from the background expression by the roundish morphology and 
higher YFP intensity. TL = transmission light, sA5-YFP = secreted Annexin V-yellow fluorescent protein and Afl = 
autofluorescence. Bars are 200 µm (A, B), 500 µm (C, D), and 200 µm (E).   
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Fig. 22. sA5-YFP marks apoptotic cells during mouse development. 
(A) Sagittal section of a transgenic E9.5 embryo showing co-localization of bright positive sA5-YFP+ signals (white arrows) 
with cCasp3 positive signals within the heart, the neural tube and the otic placode.  (B) Magnification of the heart as 
indicated by white box in (A). (C, D) Frozen sections of the neural tube region of a sA5-YFP E9.5 embryo demonstrating co-
localization of bright sA5-YFP+ signals with cCasp3 and TUNEL positive signals (white arrows), respectively. TL = 
transmission light, TUNEL = Terminal deoxynucleotidyl transferase dUTP nick end labeling and cCasp3 = cleaved caspase 
3, V = ventricle and A = atria. *Sections were stained with eGFP antibody after Antigen Retrieval treatment to detect sA5-
YFP signal. Bars are 200 µm (A), 50 µm (B), 20 µm (C) and 10 µm (D). 
 
As mentioned in section 3.3, it was observed that not all the bright sA5-YFP
+
 particles co-
localized with cCasp3 in EBs. One of the possible reasons for this is the fact that cells die at 
different time points and our system marks cells at different stages of the apoptosis cascade. 
Therefore, co-stainings for cleaved caspase 3, 8 and 7 (cCasp3, cCasp8 and cCasp7) were 
performed in sections of sA5-YFP embryos at E10.5 (Fig. 23). The pro-caspase 8 is the first 
caspase that gets activated after a death signal is sensed by death receptors (Fig.  5) and it 
further activates other caspases or molecules in both, the extrinsic and intrinsic apoptosis 
pathways. The effector casp-7 is a key protease, such as cCasp3, that further activates some 
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molecules in the nucleus; it is considered to be a point of no-return and the cell will definitely 
die. Immunostaings showed co-localization of bright sA5-YFP signals with the three markers 
(Fig. 23). It was noticed that the sA5-YFP particles co-localizing with cCasp8 had a clear 
ring-like membrane, condensed nucleus and cCasp8 was entirely distributed in the cytoplasm. 
These cells appeared to be whole and in a phase before blebbing started, indicating that they 
were at the beginning of the apoptosis cascade 
 
 
Fig. 23. sA5-YFP marks cells at different time points of apoptosis cascade during embryonic development. 
Frozen sections of sA5-YFP embryos at E10.5 showing co-localization of bright sA5-YFP+ particles with cCasp3, 7 and 8. 
Notice that cells positive for cCasp8 were intact, contained condensed nuclei and presented a clear membrane YFP ring (early 
apoptosis). Small blebs were detected to co-localize with cCasp3 and cCasp7 (intermediate-late apoptosis). *Sections were 
stained with eGFP antibody after Antigen Retrieval treatment to detect sA5-YFP signal. Bars are 10 µm, 10 µm and 2 µm, 
respectively from left to right. 
 
This was different for particles that were positive for cCasp3 and cCasp7, where very small 
blebs were also stained and had no nuclei, indicating that these cells already were in an 
intermediate/late stage of apoptosis. Finally, I could also show that few green particles co-
localized with TUNEL staining (Fig. 22). This means that the sA5-YFP
+
 signals co-localize 
with markers for early and late apoptosis. 
 
3.6. sA5-YFP marks apoptosis during mouse heart development 
There is a need for studies that reveal detailed information about the contribution of apoptosis 
in the shaping of the developing mouse heart (24). Therefore, using the sA5-YFP mice, an 
analysis of rates and localization of PCD events was performed at different embryonic stages 
of murine hearts (E9.5 – E18.5) and postnatal day 2 (P2) hearts. Bright sA5-YFP particles 
were found in histological sections from all heart stages examined (Fig. 24, Fig. 25, Fig. 26). 
This detection system was sensitive enough for the identification of apoptotic cells at very 
early stages (e.j. E9.5,Fig. 24) of mouse heart development. It could also be observed that the 
presence of the bright green particles (white arrows) decreased as the embryonic heart got 
older.  
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Fig. 24. Apoptosis patterns during mouse heart development at E9.5. 
(A) Sagittal section of a transgenic embryo at E9.5. (B) Magnification of the heart from (A) where very bright YFP+ signals 
(white arrows) mark the apoptotic cells or blebs. These were mainly found in the ventricular myocardium. cCasp3 = cleaved 
caspase 3 and V = ventricle. *Sections were stained with eGFP antibody after Antigen Retrieval treatment to detect sA5-YFP 
signals. Bars are 200 µm (A) and 100 µm (B). 
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Fig. 25. Apoptosis patterns during mouse heart development at E11.5-E12.5. 
Frontal sections of transgenic hearts at E11.5 (A) and E12.5 (C). (B and D) Magnification of areas marked in white boxes 
(A, D), where very bright sA5-YFP+ signals (white arrows) mark the apoptotic cells or blebs. These events were found 
predominantly at the ventricular trabeculae. cCasp3 = cleaved caspase 3, OFT = outflow tract, RA = right atrium, LA = left 
atrium, Tr = trabeculae, iVS = intra ventricular septum. *Sections were stained with eGFP antibody after Antigen Retrieval 
treatment to detect sA5-YFP signals. Bars are 100 µm (A), 20µm (B), 200 µm (C) and 10µm (D). 
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Fig. 26. Apoptosis patterns during mouse heart development at E13.5 and E18.5. 
Frontal sections of transgenic hearts at E13.5 (A) and E18.5 (C). (B and D) Magnification of areas marked in white boxes 
(left) where very bright sA5-YFP+ signals (white arrows) mark the apoptotic cells or blebs. These events were found 
predominantly at the ventricular trabeculae. Notice that apoptotic events decreased as the heart grows older. cCasp3 = 
cleaved caspase 3, OFT = outflow tract, RA = right atrium, LA = left atrium, Tr = trabeculae, iVS = intra ventricular septum. 
*Sections were stained with eGFP antibody after Antigen Retrieval treatment to detect sA5-YFP signals. Bars are 200 µm (A, 
C), 20 µm (B), and 10µm (D). 
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As mentioned in section 3.5, I could observe that in the sA5-YFP embryonic hearts there were 
diverse types of labeled particles, similar to the ones present in other regions of the embryo 
(i.e. neural tube). There were bright sA5-YFP spots―with an approximate diameter of 5-10 
µm―that showed clear ring-like membrane accumulation, often co-localized with cCasp3 
positive signals in the cytoplasm and presenting a condensed nucleus. These cells were 
defined as ―apoptotic cells‖ because they appeared to be intact and in a phase before 
membrane blebbing, indicating that they were at the beginning of the apoptosis cascade (Fig. 
27A). On the other hand, small particles―ranging from a diameter of 2-4 µm ―appeared to 
be fragments of apoptotic cells. They often did not contain nuclei and sometimes co-localized 
with cCasp3, indicating that these cells already were in a late stage of apoptosis. I defined 
these particles as ―blebs‖ (Fig. 27B).  
 
 
Fig. 27. Size and morphology of apoptotic cells and blebs detected by the sA5-YFP transgenic system. 
 (A) Apoptotic cells marked by sA5-YFP were defined as bigger particles (5-10 µM) that presented condensed nuclei and at 
least one of the following features: a clear ring-like membrane sA5-YFP accumulation, cCasp3 positive signal. (B) Blebs 
were defined as smaller particles (2-4 µm) without nuclear signal and positive for either YFP or cCasp3 or both. cCasp3 = 
cleaved caspase 3. *Sections were stained with eGFP antibody after Antigen Retrieval treatment to detect sA5-YFP signals. 
Bars are 5 µm (A, left) and 2 µm (A, right), 10 µm (B, left) and 5 µm (B, right).  
 
In addition, TUNEL staining was also tested to evaluate if it also co-localizes with sA5-YFP
+
 
signals in E12.5 hearts. Few TUNEL
+
 signals were found to co-localize with sA5-YFP
+
 cells 
in the whole heart (Fig. 28). As there was a higher co-localization of sA5-YFP particles with 
cCasp3 positive signals and taking into account that cCasp3 is widely recognized to detect 
early apoptosis, it was used for the analysis and quantification of apoptotic events during 
mouse heart development in all further experiments.  
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Fig. 28. TUNEL+ signals co-localize with sA5-YFP+ particles in E12.5 hearts. 
(A) An example of TUNEL+ signal co-localizing with sA5-YFP+ signal (white arrow) in frozen sections of E12.5 hearts.  
Very few TUNEL+ signals were found in the heart at this stage. Bar is 10 µm. 
 
To confirm the specificity of the system, control stainings were performed in sections from 
E12.5 hearts. First, I check if the sA5-YFP
+
 fluorescence signals were specific by detecting 
them using an anti-human Annexin V antibody. This is because the CAG-sA5-YFP plasmid 
contains the human sequence of Annexin V (108). I could prove that the native sA5-YFP
+
 
signals (Fig. 29A) corresponded to specific human Annexin 5 signals (white arrows in Fig. 
29B). Secondly, I tested if the eGFP antibody is able to detect sA5-YFP signals after antigen 
retrieval. For that, E12.5 sections of sA5-YFP
-
 (Fig. 29C) and sA5-YFP
+
 (Fig. 29D) hearts 
were stained after antigen retrieval (Method 2.4.2) with anti-eGFP and anti-cCasp3. In 
negative hearts, no eGFP signal was detected in comparison to sA5-YFP positive signals 
proving the specificity of the eGFP antibody.  
 
 
Fig. 29. Immunostainings controls in frozen sections from E12.5 hearts. 
 (A) Native sA5-YFP expression. (B) Co-localization of sA5-YFP+ signals with human Annexin V antibody. (C) Negative 
E12.5 heart section co-stained against eGFP and cCasp3. No eGFP signals were detected demonstrating eGFP specificity to 
detect sA5-YFP signals. (D) eGFP antibody detects sA5-YFP+ signals after Antigen Retrieval treatment in a sA5-YFP E12.5 
heart stained against eGFP and cCasp3. *Sections were stained with eGFP antibody after Antigen Retrieval treatment to 
detect sA5-YFP signals. Bars are 10 µm (A, C) and 5 µm (B, D).  
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3.7. Localization and quantification of dead cells undergoing apoptosis during mouse 
heart development 
To see if apoptosis is related to morphological changes in the heart, I assessed the specific 
localization of apoptotic cells and blebs during the different stages of heart development. At 
very early stages (E9.5-10.5) sA5-YFP+ particles were mainly localized to the ventricular 
myocardium (Fig. 24). Some other regions were visible at E11.5 in which very bright sA5-
YFP
+
 particles localized to both ventricles (Fig. 25), to the endocardial cushions (developing 
valves) and to the moderator band (connects the iVS to the anterior papillary muscle) close to 
the intraventricular septum (Fig. 30). At E12.5, there was a clear accumulation of apoptotic 
cells and blebs in the left ventricle (Fig. 25). In this region there were plenty of bright sA5-
YFP
+
 apoptotic cells―co-localizing with cCasp3―as well as sA5-YFP+ blebs.  
 
One day later, at E13.5, the majority of labeled sA5-YFP cells were still localized to the left 
ventricle, but to a lesser extent compared to E12.5. At this stage, it was also noticed that there 
were sA5-YFP
+
 blebs in the trabecular region, in the developing mitral valve and in the right 
atria (Fig. 31). Another study (21) has shown that apoptosis is also present in the outflow tract 
at E13.5.  However in this present work, I could only distinguish very dim and small sA5-
YFP
+
 signals, indicating that dying cells in this area could have already been engulfed or have 
been in a later stage of the apoptosis cascade (Fig. 26). At later stages of heart development, 
the apoptotic events were less frequent (Fig. 26). E.g. in P2 hearts, the apoptotic events were 
sporadically found in the ventricles and close to the mitral and tricuspid valves (Fig. 32). 
Finally, the incidence of apoptotic cells and blebs in adult hearts (11 months old) was scarce, 
indicating that the embryonic heart is primed for apoptosis, while the adult heart is not Fig. 
32. This coincides with the recent findings of Sarosiek and colleagues, who showed that the 
expression of apoptosis genes decreased in the adult heart (63). However a deeper 
characterization of sA5-YFP
+
 cells in the adult heart should be performed.  
 
As one of my aims was to provide a complete map of the apoptosis rates, I quantified all types 
of labeled sA5-YFP particles throughout heart development from E9.5 to P2 in at least 3 
hearts per developmental stage (Fig. 33). In order to summarize this information, I classified 
these particles into ―apoptotic cells‖ and ―blebs‖ as mentioned in section 3.6 (Fig. 23). For 
quantification, an ―apoptotic cell‖ was defined as the one containing nucleus and being 
positive for cCasp3, sA5-YFP or both. Similarly, a ―bleb‖ was defined as an entity not 
containing nucleus and being positive for either cCasp3 or YFP or both. The quantitation data 
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indicated that apoptosis peaks at early stages of heart organogenesis (E9.5 – E11.5), slightly 
decreased from E12.5 to E14.5, and started to further decrease at E15.5 confirming that 
apoptosis is highly active at the beginning of heart formation (Fig. 34).  
 
 
Fig. 30. Distribution pattern of apoptosis in the mouse heart at E11.5. 
(A) Frontal section of a transgenic heart at E11.5. Labeled sA5-YFP apoptotic cells and blebs (white arrows) were found at 
the trabeculae of both ventricles, in the regions of the developing mitral and tricuspid valves, in the intraventricular septum 
and in the moderator band. (B-D) Magnifications of the heart regions marked by white boxes in (A) depicting the presence of 
apoptosis. V = ventricle, AVC = atrioventricular cushion, RA = right atrium, LA = left atrium, Tr = trabeculae, MB = 
moderator band (connects the iVS to the anterior papillary muscle), DTV = developing tricuspid valve and DMV = 
developing mitral valve. Bars are 200 µm (A), and 10 µm (B, C, D).   
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Fig. 31. Distribution pattern of apoptotic cells in the mouse heart at E13.5. 
(A) Frontal sections of a transgenic heart at E13.5. Labeled sA5-YFP apoptotic cells and blebs (white arrows) were found at 
the trabeculae of both ventricles, in the developing mitral valve and in the right atria. (B-D) Magnifications of the heart 
regions marked by white boxes in (A) depicting the presence of apoptosis.  V = ventricle, RA = right atrium, LA = left 
atrium, Tr = trabeculae, and DTV = developing tricuspid valve. Bars are 200 µm (A) and 10 µm (B-D). 
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Fig. 32. Distribution pattern of apoptotic cells in P2 and adult mouse hearts. 
(A) Frontal section of a transgenic heart at P2. Labeled sA5-YFP apoptotic cells and blebs (white arrows) were scarcely 
found in the epicardium. (B) Magnification of the heart region marked by white boxe in (A) depicting the presence of 
apoptosis. (C) Transversal section of a transgenic heart at 11 months old. Labeled sA5-YFP apoptotic cells and blebs (white 
arrows) were scarcely found in the compact zone of the left ventricle. (D) Magnification of the heart region marked by white 
boxe in (C) depicting the presence of apoptosis. RA = right atrium, LA = left atrium, LV = left ventricle, RV = right 
ventricle, YFP = yellow fluorescence protein, Afl = autofluorescence channel. Bars are 500 µm (A, C) and 20 µm (B,D). 
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Fig. 33. Quantification of all different types of particles marked with sA5-YFP and cCasp3 during embryonic heart 
development. 
 (A, B, C) The graphs at the left show normalized rates of cells marked by sA5-YFP, cCasp3 or both, containing condensed 
nuclei to all nuclei. (D, E, F) Graphs at the right revealed the normalized rates to all nuclei of cells marked by sA5-YFP, 
cCasp3 or both, but without nuclei. Pictures in each graph are example of each type of quantified particle. eGFP = enhanced 
green fluorescent protein* and cCasp3 = cleaved caspase 3. *Sections were stained with eGFP antibody after Antigen 
Retrieval treatment to detect YFP signals. Bars are 10 µm in (A and D) and 5 µm in (B, C, D, E).  
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Fig. 34. Apoptotic cells and blebs rates during heart development. 
(A) Quantitation of total apoptotic cells. Apoptosis peaks at early stages of heart development (E9.5 - E11.5) and it decreases 
significantly after E15.5 (T-test between E9.5 vs E15.5, p-value = 0.011). (B) Quantitation of total blebs. Apoptosis peaks at 
early stages of heart development (E9.5 - E11.5) and it decreases significantly after E15.5 (T-test between E9.5 vs E15.5, p-
value = 0.011). (C) Fold of YFP+ per cCasp3+ signals at different stages of mouse heart organogenesis. YFP+ signals were 
approximately twice the cCasp3+ signals mainly found at the trabeculae while cCasp3+ signals were mostly found at the 
outflow tract. Data are shown as mean ± s.e.m., n=3. *Sections were stained with eGFP antibody after Antigen Retrieval 
treatment to detect YFP signals. Bars are 5 µm.  
 
An advantage of the sA5-YFP detection system is that it allows detecting blebs of dying cells 
enabling the identification of cells in later stages of the apoptosis cascade, which is not 
possible with antibodies specific to either earlier or later stages at which most of the cells 
have been engulfed already. There were approximately two fold more sA5-YFP signals than 
cCasp3 signals (Fig. 34C) indicating that this system allows the detection of a broader 
spectrum of apoptotic stages and it can probably also detect other types of programmed cell 
death.  
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3.8. Cardiomyocytes predominantly undergo apoptosis during mouse heart development 
An advantage of the sA5-YFP system is that it allows for the detection of apoptosis at early 
stages prior to the disruption of the cell membrane. To identify the cell types undergoing 
apoptosis in the embryonic heart, co-stainings in sections of transgenic E13.5 embryonic 
hearts with typical markers for cardiomyocytes (α-actinin and MF20), endothelial cells 
(PECAM), leukocytes (CD45) and smooth muscle cells (α-smooth muscle actin, ASMAC) 
were performed. Immunostainings revealed a strong co-localization between cardiomyocytes 
and sA5-YFP positive signals (Fig. 35A, B). Quantification indicated that approximately 66% 
of the sA5-YFP
+
 cells were cardiomyocytes, 12% smooth muscle cells, 7% leukocytes, 8% 
endothelial cells and 7% mesenchymal cells. This data clearly show that cardiomyocytes are 
the most abundant apoptotic cell type during heart development (Fig. 35G).   
 
 
Fig. 35. Identification of cell types undergoing apoptosis during heart development. 
(A, F) Co-stainings in Sections of transgenic embryonic hearts (E13.5) stained for markers of cardiomyocytes (CMs, α-
actinin and MF20), endothelial cells (ECs, PECAM), leukocytes (LCs, CD45), smooth muscle cells (SMCs, ASMAC) and 
mesenchymal cells (MCs, vimentin). (G) Quantitation of the different cell types that undergo apoptosis during heart 
development. Data are shown as mean ± s.e.m.,*P < 0.05 (Student's t-test), n=3. Bars are 5 µm (A, B), 10 µm (C, F) and 20 
µm (D, E). 
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3.9. Real-time detection of massive apoptosis by sA5-YFP during mouse development 
To prove that the sA5-YFP transgenic mouse line is a powerful tool to visualize apoptotic 
cells in living embryos, I monitored the accumulation of sA5-YFP at the membrane of dying 
cells in transgenic embryos at E8.75 over time. After dissecting the sA5-YFP embryos from 
the uterus and yolk sac, I placed them in an imaging chamber filled with IMDM-imaging 
medium. Then, I induced massive cell death by medium starvation and analyzed the onset of 
apoptotic cells under an inverted confocal microscope at 37°C and 5% CO2 for 15 - 20 h 
taking z-stack pictures every 6 - 10 min (Fig. 14).  
 
As shown in Fig. 36-B, I observed a clear increase in accumulation and fluorescence intensity 
of sA5-YFP in the membrane of dying cells throughout the whole embryo. Very bright sA5-
YFP signals, with a ring-like morphology, were visible around the heart area after 2 h of 
induction (white arrows). After 6 - 10 h more cells rounded up and detached from the tissue in 
the regions close to the otic ring and neural tube. Approximately after 11 h, some of the bright 
sA5-YFP+ signals seem to disappear, indicating that they could have been phagocytosed by 
surrounding cells or macrophages. It is important to mention that the embryo shrinks and dies 
after 8 h of imaging.   
 
 
Fig. 36. Long term observation of cell death in a E8.75 sA5-YFP embryo. 
(A) A transgenic sA5-YFP embryo was observed under an inverted confocal microscope. Massive cell death was induced by 
medium starvation. After 2 h, the first rounded cells (white arrows) appeared. Time-lapse images were recorded every 5 min 
for 15 h. 33 z-stack slices of 4 µm were taken. Images in this figure are from the z-stack #17. (B) Quantitation of sA5-YFP 
fluorescence signals from (A) over time. Bars are 100 µm. 
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3.10. Real-time detection of apoptosis by sA5-YFP during cranial neural tube closure 
and heart development 
After proving that sA5-YFP detects dying cells in vivo after induction of apoptosis, it was of 
interest to evaluate physiological cell death during embryonic development in vivo. 
Yamaguchi and colleagues (107) demonstrated that apoptosis occurs during neural tube 
closure (NTC) by using their specific transgenic mouse (SCAT). This system enables the 
monitoring of caspase-3 activity based on fluorescence energy transfer (FRET) between two 
fluorescent proteins (ECFP and Venus), which are linked by the cleavage sequence of caspase 
3 (DEVD). 
  
In analogy, the sA5-YFP system should also detect apoptotic cells at the neural ridges and 
midline of the neural tube during fusion.  
 
In a collaboration, Prof. Masayuki Miura and Dr. Yoshifumi Yamaguchi from the University 
of Tokyo, Japan kindly imaged the neural tube closure in sA5-YFP embryos. Transgenic E8 
sA5-YFP embryos were dissected from the uterus and their yolk sacs. Embryos expressing 
sA5-YFP were placed into a 35mm glass-bottom dish filled with culture medium and imaged 
under an inverted confocal microscope at 37°C and 5% CO2 for 10 h. After 18 min, the first 
rounded cells labeled by sA5-YFP appeared (Fig. 37A-B). In a similar way as with the SCAT 
system, ―dancing apoptotic cells‖ were detected, which kept their round shape and moved to 
the dorsal ridges of the neural plate—without being engulfed—for about 6h. With these 
experiments, I could conclude that sA5-YFP is able to detect apoptotic cells in-vivo in specific 
tissues during mouse development.  
 
76 
 
 
Fig. 37. Real-time detection of apoptosis by sA5-YFP during cranial neural tube closure. 
(A) A transgenic E8 sA5-YFP embryo was dissected from the uterus and its yolk sac. It was transferred to a 35mm glass-
bottom dish filled with culture medium and positioned under an inverted confocal microscope. The embryo was imaged at 
37°C and 5% CO2. (B) Time lapse of the area marked by a white box in A. After 18 min, the first rounded cells labeled by 
sA5-YFP (white arrows) appeared. Notice that these cells stayed (dancing like) in this area without being engulfed for about 
6h. (C) Quantitation of sA5-YFP fluorescence signals from (B) over time. Bars are 100 (A), 40 μm (B, C). (Images and graph 
were kindly provided by Dr. Yoshifuma Yamaguchi and Prof. Masayuki Miura from the University of Tokyo, Japan) 
 
A similar experimental protocol was performed to observe apoptosis during heart 
development. Transgenic embryos were isolated at E9 and immersed into 2% low-melting 
agarose in a glass imaging chamber filled with culture medium. The same culture conditions, 
as in section 3.9, were used (Method 2.6). The imaging was performed by using confocal 
microscopy for 20 h. A clear increase in accumulation of sA5-YFP in the membrane of dead 
cells in the ventricle, the epicardium and the outflow tract was observed. After 6 h, the first 
rounded cells and blebs (indicated by a white plus sign in Fig. 38A) appeared in the right 
ventricle, the left epicardium, and the outflow tract. Furthermore, it was noticed that some 
dying cells appeared and disappeared over time (yellow box in Fig. 38A) indicating that they 
could have been phagocytized by macrophages or by other engulfing cells. Some of the sA5-
YFP
+
 cells preserved their roundish morphology for the whole time imaging of (arrows in the 
ventricle). This can be also observed by the increase in fluorescence when the dying cells 
appeared, the drop in intensity when they disappeared and finally another increase when new 
dying cells appeared (Fig. 38B).  
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Fig. 38. Long term observation of physiological cell death in a sA5-YFP embryonic heart at E9. 
A transgenic sA5-YFP embryo was dissected from the uterus and yolk sac at E9. It was placed sagittal into 2% low 
temperature-melting agarose contained in a special chamber filled with culture medium. The embryonic heart was observed 
under an inverted confocal microscope under 37°C and 5% CO2 conditions for 20 h. (A) A clear increase in accumulation of 
sA5-YFP in the membrane of dead cells was observed in the ventricle, epicardium and outflow tract. Bar is 100 µm. After 1 
hour, the first rounded cells and blebs (white plus signal in yellow square) appeared in the outflow track. Notice that cells 
marked with a white arrow stayed there during the whole time of imaging. (B) Fluorescence intensity of the region marked in 
yellow box in (A). Time-lapse images were recorded every 10 min, Z-stack slices were taken and the images in this figure are 
maximum projections.  
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4. DISCUSSION  
The motivation of this work was to expand the current knowledge of the role of apoptosis in 
the developing mouse heart. This might serve as the basis for developing new therapies to 
treat cardiovascular diseases. For that, I established the CAG-sA5-YFP genetic system to 
visualize and analyze the rates, localization and identity of apoptotic cells in the embryonic 
mouse heart in vivo.  
 
The functionality and specificity of the CAG-sA5-YFP reporter was first evaluated in vitro, in 
undifferentiated and differentiated mESCs, as well as in vivo in a transgenic mouse model 
generated from the sA5-YFP mESCs. In vitro, I showed that the sA5-YFP mESCs 
ubiquitously expressed sA5-YFP and that ectopically induction of apoptosis by 4-OHT, led to 
accumulation of the protein in the membrane of apoptotic cells, resulting in an increased 
intensity of yellow fluorescence. In addition, it was also proven that the sA5-YFP system can 
detect physiological apoptosis in differentiated mESCs (EBs). I observed several sA5-YFP 
labeled apoptotic cells in the middle and peripheral regions of the EBs. In addition, I noticed 
that these cells were mostly in early stages of the apoptosis cascade as marked by the early 
apoptosis marker, cCaps3, and that very few cells co-localized with the late marker of 
apoptosis, TUNEL.  
 
The in vivo validation consisted of generating a sA5-YFP transgenic mouse line and 
demonstrating that sA5-YFP
+
 cells were localized in embryonic regions where apoptosis 
occurs (i.e. brain, yolk sac and otic ring). In addition, these sA5-YFP labeled cells were 
classified as ―apoptotic cells‖ and ―blebs‖ and were confirmed to be apoptotic cells by co-
immunostainings for cCasp3. Moreover, this system proved to be reliable to visualize 
apoptotic cells in living-embryos. As positive controls, massive cell death was induced in 
living E8.75 sA5-YFP embryos and sA5-YFP
+
 cells appeared, detached from the tissues and 
presented typical apoptosis features. Additionally and very importantly, the sA5-YFP system 
enabled the detection of apoptotic cells during neural tube formation as has already been 
shown by Yamaguchi and colleagues (107).  
 
After all these validation steps, I evaluated if apoptosis occurs during mouse embryonic 
development and provided a complete map of the distribution and frequencies of apoptotic 
cells and blebs during the complete heart embryogenesis (E9.5 to P2). Apoptosis peaked at 
early stages of development and decreased as the heart grew older. Apoptotic events were 
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observed in the ventricular trabeculae, indicating that apoptosis might be critical for trabecular 
formation. In addition, I confirmed that mainly cardiomyocytes undergo apoptosis in the 
embryonic heart.  
 
In the following sections, I will discuss the advantages and limitations of the sA5-YFP 
system, the possible role of apoptosis in the developing heart, as well as the probable 
applications of this live-imaging tool.  
 
4.1. The sA5-YFP system: a straight forward genetic reporter to visualize apoptosis 
during mouse development in vivo 
The sA5-YFP mouse line, established in this work, is one of the few genetically encoded 
reporter tools available, which can reveal spatiotemporal changes and dynamics of apoptotic 
cells during mouse development in vivo. Labeled sA5-YFP cells show typical morphological 
and biochemical features of apoptotic cells. They round up, detach from tissue boundaries and 
their chromatin condenses. The sA5-YFP protein binds to PS residues exposed in the outer 
layer of the apoptotic membrane and it co-localizes with active forms of pro-caspases 
(caspase 8), effector caspases (active caspase 3 and 7) and with TUNEL staining. 
Furthermore, blebs of sA5-YFP labeled cells can be detected before they are engulfed, 
proving that the sA5-YFP reporter allows the visualization of cells in different stages (early-
intermediate-late) of apoptosis. Moreover, the sA5-YFP system allows isolation of these blebs 
also called membrane-bound extracellular vesicles, by fluorescence-activated cell sorting 
(FACS) or centrifugation, for further analysis. 
  
According to the Nomenclature Committee on Cell Death (NCCD) ―in vivo studies constitute 
the ultimate tool to recognize the true importance of cell death signaling pathways and to 
understand their regulation‖ (8). However, there are still very few live-imaging tools to 
visualize different types of programmed cell death in mammals (21, 24, 95, 107, 149-152). Of 
those, the transgenic mouse line (SCAT3) developed by the group of Professor Masayuki 
Miura stands out. It enables the monitoring of casp-3 activity based on fluorescence energy 
transfer (FRET) between two fluorescent proteins (ECFP and Venus), which are linked by the 
cleavage sequence of caspase 3 (DEVD). Yamaguchi and colleagues used this mouse to 
describe the role of apoptosis during neural tube closure (107).  
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The SCAT3 system provides reliable detection of apoptosis. However, the quantification of 
caspase activation depends on a complex post-imaging processing. To track apoptotic cells, 
Yamaguchi and colleagues calculated the Venus/ECFP (V/C) ratio. These measurements 
require a considerable amount of time to make a precise analysis and involve different criteria 
to discard the noise (±10%) of the V/C. In contrast, the sA5-YFP model allows direct 
visualization and quantification of apoptotic cells and blebs during long-term observation. 
The sA5-YFP intensity can be automatically calculated directly after the time-lapse 
experiment. In addition, the appearance, trajectory and disappearance of apoptotic cells and 
blebs can be distinguished without the need of further measurements. This is not possible to 
track with probes or antibodies which are specific to only one time point of the apoptotic 
cascade (early or late), when the caspase signal disappear or when most of the apoptotic blebs 
have been engulfed already.  
 
The SCAT3 and the sA5-YFP are powerful live-imaging systems. Both can track 
physiological and non-physiological apoptosis in living mouse embryos at earlier stages (E8-
9.5) for about 8 hours, continuously (107). Using these reporter lines, distribution and 
morphological changes of apoptotic cells within specific tissues can be described over time. 
For example, with the SCAT3 transgenic mouse line, it was possible to identify two different 
types of dying cells during neural tube closure. The ―dancing‖ ones (D-type) that were 
localized at the edge of the neural ridge. These cells present non-typical apoptosis 
characteristics, they seem to detach from the rest of the tissue and stay there without 
undergoing fragmentation (bleb formation) for more than 3 hours of imaging time. They are 
round in shape and with a diameter size of around 10 µm. The second type (C-type), were 
cells with typical apoptotic features. They appeared within the tissue, they have smaller 
diameter size (3 -7 µm), they form blebs after casp-3 activation and finally, they disappear 
from the tissue. Similarly, sA5-YFP
+
 apoptotic cells and blebs were observed during the 
neural tube closure using the sA5-YFP.   
 
These apoptotic features and cell patterns were found in E8.75 sA5-YFP embryos after 
exposition to massive cell death. Different bright sA5-YFP
+
 cells detaching from the neural 
tube, the heart, and the otic ring were detected. It is known that environmental stress caused 
by medium depletion induces different types of programmed cell death such as apoptosis, 
necroptosis and autophagy (97, 153, 154) due to the lack of nutrients, changes in pH and 
oxygen availability. However, it was clearly demonstrated in tissue sections of E9.5 – 10.5 
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sA5-YFP embryos that the bright sA5-YFP
+ 
particles co-localized with cleaved caspase 8, 3 
and 7, meaning that they were mainly apoptotic cells. These cells presented the typical series 
of morphological and biochemical features of apoptotic cells, including plasma membrane 
blebbing, rounding up and shrinkage of the cell and nuclear condensation-fragmentation 
(155).  
 
One big advantage of sA5-YFP over the SCAT3 system is the stability of sA5-YFP after 
tissue fixation. Embryos at different developmental stages can be fixed and co-stained with 
other apoptosis and cell type markers. While embryos in the SCAT3 system have to be 
stained for casp-3 or 7 and it is not possible to observe co-localization of SCAT3 expression 
with these markers. In this way, the sA5-YFP is an all-inclusive tool specific for apoptosis, 
provides more information about cell types undergoing cell death and apoptosis rates in fixed 
tissue, ex-vivo, and in-vivo.  
 
4.2. Apoptosis is present in the embryonic mouse heart during all stages of development 
Tracking dying cells is very challenging due to the fast speed and asynchrony of the apoptosis 
cascade. Different cells within tissues are engulfed, shed or dispersed within minutes (72). It 
is known that each cell has different dying progression kinetics (71, 98). Therefore, 
techniques based on end time point detection (e.g. TUNEL assay or caspases activation) can 
lead to misinterpretations or false-positive quantitative results. This is one of the reasons for 
the many uncertainties and discrepancies in the estimation of apoptosis rates in the 
myocardium (20). Despite the effort of several research groups in investigating the role of 
apoptosis in the developing heart (21, 40, 44, 156-159) and in the diseased heart (47, 57, 92, 
101, 102, 160, 161), still many questions remain unsolved such as: the time course and 
duration of the apoptosis cascade (morphological and morphological changes of apoptotic 
cells), the mechanism of removal of dead corpses, the cell types undergoing apoptosis and an 
accurate quantification throughout the stages of heart organogenesis.  
 
Using the CAG-sA5-YFP mice, it was possible for the first time to give a complete map of 
the distribution and incidence of apoptotic cells and blebs in the embryonic mouse heart from 
E9.5 to P2. The quantitation data indicated that apoptosis peaks at early stages of heart 
organogenesis (E9.5 – E13.5) and decreases from E15.5 onwards. With both quantified 
parameters, marked sA5-YFP
+
 apoptotic cells with condensed nuclei and sA5-YFP
+ 
blebs 
without nuclei, the percentage of apoptosis was less than 1.5 % between E9.5-E11.5, less than 
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0.5% from E12.5 – E14.5 and less than 0.25% from E15.5 to P2. This correlates with the 
results presented by Sharma and colleagues (43). They quantified the number of high-intense 
and low-intense TUNEL
+ 
signals divided by the total number of cells per template (apoptosis 
index) in mouse hearts from E10.5-E11.5. Similarly to the sA5-YFP quantification, they 
claimed that less than 1% of the apoptotic cells with low-intense signals were found 
throughout the analyzed embryonic mouse hearts.  
 
On the other side, Sharma et al., also observed that high levels of apoptosis (more than 4%) as 
measured by TUNEL
+
 nuclei, occur at E12.5-E13.5 at the endocardial cushions in the OFT. 
Likewise, Abdelwahid and coworkers (44) reported that between 2 - 4 % of apoptotic cells 
(TUNEL
+
 signals) are present in the ventricular wall of hearts among E11.5 – E14.5 
decreasing to less than 0.5 % after E16.5. This was not observed in E12.5 sA5-YFP hearts in 
which TUNEL
+
 signals were rarely found per section and from these very few co-localized 
with apoptotic cells marked by sA5-YFP. This observation matches the remarks made by Van 
Ham and colleagues (108) in the secA5-YFP zebrafish system. They noticed that the brightest 
TUNEL
+
 signals were not positive for YFP and showed no nuclear staining. They concluded 
that these cells were in the final stage of apoptosis where DNA fragmentation is massive and 
apoptotic cells do not have a defined cell membrane and nucleus. 
 
From these data, I observed that the percentage of apoptosis present in the embryonic heart is 
high, compared to the reported basal levels in the adult heart (≤1.5% vs. 0.001%, respectively) 
(162, 163). A precise estimation of apoptosis rates is critical to know, as slight variations in 
the apoptotic cell number could lead to heart failure. For example, Kitsis and colleagues 
showed that that apoptotic rates of less than 0.023% are sufficient to induce a lethal, dilated 
cardiomyopathy in adult mouse hearts using an elegant inducible transgenic system for 
caspase 8 activation (163). These levels of apoptosis are four-to tenfold lower than the one 
reported in other studies (101, 102). To know, if apoptosis inhibition might constitute the 
basis to develop new therapies, it is critical to make a precise calculation of the apoptosis rates 
during heart development and in the adult heart. Kitsis and coworkers proved that the specific 
inhibition of caspase activation by the polycaspase inhibitor IDN 1965 prevented the 
development of cardiomyopathy. Another study from Sarosiek and colleagues (63) confirmed 
that the embryonic and postnatal heart is primed for apoptosis. When young hearts are 
exposed to death signals such as irradiation or chemotherapy agents used in young cancer 
patients, these patients developed cardiotoxicity. They proved that suppression of genes from 
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the intrinsic apoptosis pathway (e.i. Bax and Bak) reversed the effects caused by the death 
ligands. In this project, I corroborated that apoptosis is high at early stages of heart 
development and decreases in later stages coinciding with the reports of Kitsis and Sarosiek 
discussed in this paragraph.  
 
4.3. The sA5-YFP system overcomes limitations of single apoptosis endpoint 
measurements  
One of the most used assays for detecting apoptosis in heart tissue is TUNEL. However, it has 
been observed that the numbers of cells undergoing apoptosis in the heart could be 
overestimated when techniques based on DNA end-labeling are used. For example, several 
groups have reported high rates (5 to 35%) (20, 101) or lower rates (0.023 to 2.5 %) (102, 
163, 164) of apoptosis in hearts of patients with late-stages of dilated cardiomyopathy. This 
indicates that even if TUNEL assay has been widely accepted as apoptosis marker, it can lead 
to false-positive results (19, 100). As it is a DNA fragmentation-based method it is not known 
how much DNA has to be fragmented until the TUNEL method gives a positive signal (20). 
In addition, it has been shown that TUNEL labels not only apoptotic but also oncotic nuclei 
(165), as well as nuclei undergoing DNA repair (166) and duplication (100). Therefore, 
critical caution has to be taken whenever DNA-fragmentation-based analysis is performed.  
 
In addition, as the NCCD recommends, it is necessary to use at least two biochemical 
methods besides morphological characteristics to define the type of programmed cell death 
(103). Therefore, the previous studies discussed in this section, have to be complemented and 
confirmed by other analysis using different detection techniques that cover the whole range of 
the apoptosis cascade. It is important to highlight that the sA5-YFP detection method meets 
these criteria. It combines the detection of morphological changes and the biochemical 
changes of PS translocation to the outer membrane of apoptotic cells and it can be combined 
with immunostainings to detect chromatin condensation and caspases activation. 
 
4.4. Apoptosis may play a role in the remodeling of the ventricular chamber during 
heart development 
It has been previously reported that apoptotic cells are present in specific areas within the 
developing avian and mammalian heart at specific time points. The main locations of 
apoptosis in chicken, mouse, rat, and human, that have been reported so far, are the outflow 
tract cushions, the atrioventricular cushions, walls of the aorta and pulmonary trunk and the 
interventricular septum (167). These areas suffer striking morphological changes, remodeling, 
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and septation. For example, it has been demonstrated that apoptosis in the outflow tract is 
needed for its correct shortening and its separation into the aorta and pulmonary trunk (21, 40, 
42, 158). Likewise, the incidence of apoptosis in the atrioventricular cushions correlates with 
their reshaping to form the atrioventricular valvar leaflets at E13.5 in the mouse heart (43). 
Using the sA5-YFP mice, it was possible to identify apoptotic cells and blebs in the 
ventricles, in the endocardial cushions at E11.5 - E12.5, in the atrium and in the apex of the 
interventricular septum from E11.5 – E13.5 (Fig. 25, Fig. 31), confirming previous research.  
 
In despite of the efforts of several groups, the role of apoptosis in the developing of the heart 
chambers and trabeculae is still not clear, especially in a complex model such as the mouse 
heart, due to the lack of accurate detection techniques. Until to date, different studies have 
shown that the most prominent area of apoptosis in the ventricles is the interventricular 
septum and compact myocardium in the early embryonic mouse heart. Abdelwahid and 
colleagues (44) found that the peak of TUNEL
+ 
foci at E13.5 was in the apex of the 
interventricular septum, in the compact myocardium and to a lesser extent in the trabeculae of 
the murine heart. In contrast, one year later another study showed that the number of apoptotic 
cells marked by TUNEL staining in the trabeculae increased progressively from E13.5 to P2 
(168). However, Sharma and colleagues (43) as well as Barbosky and colleagues (21) have 
shown that apoptosis in the trabeculae occurs only at very low level than in other regions (21, 
43). Due to the low detected apoptosis incidence in this region, cell death in the trabeculae 
can be easily missed. 
 
In contrast to earlier studies, apoptotic events in sA5-YFP hearts were observed for the first 
time in the primitive ventricle at E9.5 and in the trabeculae of both ventricles from E10.5 - 
E14.5. The early detection of apoptotic cells by sA5-YFP, before they are engulfed, is the 
difference of these clear findings in comparison with the techniques (TUNEL, Lysotracker 
Red) used in previous studies. The sA5-YFP apoptotic bodies were localized at the lining of 
the ventricular trabeculae (Fig. 30, Fig. 31) coinciding with episodes of trabeculae formation, 
differentiation, remodeling, and compaction. As reviewed in section 1.2.1 remodeling of 
trabeculation of both, ventricles and atria, is a critical process for chamber maturation and 
formation of papillary muscles and pectinate muscles, respectively.  
 
According to the review articles of Sedmera and colleagues (28) and Samsa and colleagues 
(25), trabeculations are first evident after cardiac looping around E9.5 - E10.5 in the mouse 
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heart. They are formed due to the self-contraction and differentiation of the myocardial cells 
adjacent to the luminal side of the primitive ventricle (Fig. 3A-B). Here, the trabecular ridges 
are spaced at regular intervals along the ventricle. These first signs of trabeculae formation 
were observed in sA5-YFP embryos at E9.5 and coincided with the presence of bright sA5-
YFP
+
 particles throughout the ventricle (Fig. 24). In further developmental stages, between 
E11.5 - E13.5, the trabeculae are extensive, they grow centripetally towards the lumen and 
have a similar pattern in both ventricles. Cardiomyocytes in the trabecular luminal side are 
more differentiated than those in the compact myocardium (Fig.  3). Surprisingly, numerous 
labeled sA5-YFP apoptotic bodies were mainly found in the ventricular trabeculae close to the 
developing valves and in the non-compact zone, where the cardiomyocytes are more 
differentiated, at E12.5 and E13.5. This occurs just before the trabeculae fuse to form the 
papillary muscles and re-orientate towards the outer myocardium at E14.5 to start 
compaction. From E14.5 onwards, cardiac septation ends and the trabeculae start thickening 
due to compaction. It is here where the myocardial mass increases, the proliferation rates in 
the compact layer and coronary vessels rise and capillaries invade the chambers (Fig.  3D). 
Apoptotic bodies marked by sA5-YFP were scarcely found in the compact myocardium from 
E15.5 onwards suggesting that apoptosis is switched off as the heart grows older in agreement 
with other studies (63, 159, 169).  
 
Trabeculae are needed to provide sufficient pumping function during growth, to separate 
blood currents in the pre-septation heart and to facilitate oxygen and nutrient exchange in the 
embryonic myocardium before coronary vascularization (33). Changes in shape and 
proportions of compact and trabecular myocardium have been observed in congenital 
morphological and functional abnormalities. Human hearts with different cardiomyopathies 
have shown left ventricular non-compaction, hypertrabeculation (abnormal numbers and 
thickness of trabeculae) and right ventricular disorders (170).  
 
Genes such as NRG1 (Neuregulin-1), ERBB2 (Receptor tyrosine-protein kinase), FKBP12 
(Peptidyl-prolyl cis-trans isomerase), Bmp10 (Bone morphogenetic protein), Nkx2.5 
(Homeobox 5-containing transcription factor), among others, are involved in trabecular 
formation and remodeling (25, 28, 171). For example, it has been demonstrated that 
transgenic over-expression of Bmp10 in developing heart leads to excessive trabeculation and 
severe heart failure (171). FKBP12-deficient mice die around E14.5 due to severe cardiac 
defects. These embryonic hearts present increased number and thickness of ventricular 
86 
 
trabeculae, deep inter-trabecular spaces, thin compact area and prominent ventricular septal 
defect. These features are similar to those of patients with left ventricular non-compaction 
(172). In addition, NRG1, ERBB2, and ERBB4 deficiency results in embryonic lethality due 
to the absence of trabeculation (25).  
 
The exact role of apoptosis in congenital heart diseases, such as non-compaction defects, is 
still not completely determined. However, there is some evidence that apoptosis dysfunction 
is associated with heart anomalies. Left ventricular non-compaction is related with mutations 
in the mitochondrial genome that leads to downregulation of apoptosis (53). This coincides 
with studies showing that apoptosis in the ventricular wall during development is mediated by 
proteins of the mitochondrial pathway (44, 63, 169). In addition, hearts of knockout mice of 
apoptosis genes such as casp-3, 7, 8, FADD and c-FLIP developed noncompact 
myoarchitecture (53, 61). Taking all together, the sA5-YFP mouse model can help to further 
investigate the role of apoptosis in normal and abnormal trabeculae formation. Co-stainings 
for genes such as Nrg1, ErbB2, ErbB4 and Bmp10 can be performed in sA5-YFP heart 
sections to evaluate if apoptosis is related to trabeculae formation and remodeling. In addition, 
the sA5-YFP mouse can be crossed to knockout models such as the FKBP12-deficient mice 
mentioned above to further investigate in detail the role of apoptosis in non-compaction 
defects. 
 
4.5. Cardiomyocyte apoptosis in the embryonic mouse heart correlates with changes in 
remodeling and differentiation 
For several years, it was not completely clear which cells will undergo apoptosis to achieve a 
proper heart formation. In the 60’s, degenerating cardiac muscle cells in the developing 
ventricular muscle were observed in the developing chick ventricle using electron 
microscopy. These cells were mainly found in large intercellular spaces or engulfed by 
phagocytes (39). Other studies in the 90’s, claimed that apoptotic cells in the endocardial 
cushions were mainly from non-myocardial origin (i.e. neural crest-derived) (46, 157, 167, 
173). In the 2000s, some works in chick (42, 158) and mouse (21, 43, 44) (174) suggested that 
cardiomyocytes undergo apoptosis in the outflow tract, endocardial cushions, and ventricular 
chamber. Consistently, in this work it was clearly demonstrated that the labeled sA5-YFP 
apoptotic cells, found in the trabeculae, co-localize mainly with cardiomyocytes around days 
E13.5 – E14.5 of mouse heart development.  
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These results are consistent with previous research in which it was observed that cleaved 
caspase 3 staining co-localized with cardiomyocyte markers (α-Actinin and MF20) in the 
developing mouse heart (21). These apoptotic cardiomyocytes were localized in the OFT and 
the lining of trabeculae in E13.5 – E14.5 heart sections. This study provided good evidence 
that many dying cells at these sites were apoptotic cardiomyocytes. However, it was limited 
by not showing co-localization of cardiomyocytes markers with the apoptotic cells labeled by 
LTR or TUNEL. The authors, themselves, mentioned that these techniques are not the most 
adequate to determine the cell type undergoing apoptosis because they label lots of apoptotic 
debris which lack membrane epitopes or apoptotic particles that have been already 
phagocytized by neighboring cells.  
 
In contrast, by using the sA5-YFP system it was possible to identify and for the first time 
quantify the correlation of apoptotic cells and blebs with their specific cell type before cell 
membrane disruption. It is known that around E13.5 - E14.5 the mouse heart consists of 4 cell 
layers (Fig.  3). Through co-stainings for different cell types in sA5-YFP heart sections, it was 
found that more than 66% of the labeled sA5-YFP cells were cardiomyocytes at E13.5. The 
rest were smooth muscle cells, leukocytes, endothelial cells and mesenchymal cells (Fig. 35). 
This is consistent with other studies that have qualitatively identified by using electron 
microscopy and histological analysis that endocardial, mesenchymal, and mainly myocardial 
cells undergo apoptosis in the embryonic mouse heart (21, 44, 174).  
 
Cardiomyocyte apoptosis in the developing heart has been related to areas of remodeling and 
differentiation. Apoptotic cells have been found to be distributed mainly in the differentiated 
parts of the mesenchyme of the endocardial cushion around E11 – E14 of mouse heart 
development. Differentiation of endocardial cushions into valvuseptal tissue correlates with 
expression of the bone morphogenic proteins Bmp-2, Bmp-4 and the homeobox gene Msx-2 
(158, 174). These proteins are generally involved in morphogenesis, cell differentiation and 
induction of apoptosis (174, 175). In addition, work performed in embryonic chick heart 
suggest that apoptosis is related to differentiation of the cardiac conduction system as 
apoptotic cells were found in the trabeculae (158). Furthermore, apoptosis might be related to 
perinatal maturation of cardiac muscle fibers in the ventricular chamber (49). Similarly, in the 
sA5-YFP hearts at E11.5 – E14.5 apoptosis was mainly found in the ventricular trabeculae 
where cardiomyocytes are more differentiated than in the compact zone (28, 176). These 
findings imply a role of cardiomyocyte apoptosis in ventricular differentiation. However, gene 
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expression patterns for genes involved in trabeculae formation, as suggested in section 4.4, 
should be performed to clearly correlate apoptosis with areas of differentiation.  
 
4.6. Relevance of the sA5-YFP system as in vivo marker of cardiovascular diseases  
As already mentioned, inhibition of apoptosis might be used as a treatment for heart diseases. 
For example, Sarosiek and colleagues (63) have recently shown that young patients treated 
with radiation or genotoxic chemotherapies develop cardiotoxicity. Hearts of these children 
were characterized by reduced ejection fraction, thin ventricular walls, and altered myocyte 
architecture. This side effect was not present in adult patients. The cause was linked to a high 
activity of the intrinsic apoptosis pathway at early stages of life. Mitochondrial pro-apoptosis 
factors such as BAK and BAX, are highly expressed in young hearts, but they are nearly 
absent in adulthood. Thus, young hearts are prone to apoptosis in response to genotoxic 
damage. Inhibition of both of these proteins in mice mitigates the cardiotoxicity effects. 
Similarly, stimulation of the expression of anti-apoptotic proteins in the mitochondria, such as 
Bcl-xL protein, may reduce myocyte cell loss caused by high apoptosis rates found in hearts 
of E17.5 and P1 mice lacking cardiac muscle α-actin (49). These results are consistent with 
the findings presented in this work. Using the sA5-YFP mouse it was shown that apoptosis 
strongly decreases from E15.5 onwards. Thus, confirming that apoptosis is switched off in 
later adult stages and it may be switched on again (44, 159) after a strong cellular stress 
caused by, for example, myocardial infarction or ischemia reperfusion (177). 
 
It is noteworthy to again mention that the accurate detection of apoptosis in healthy or 
diseased hearts is critical to understand to which extent apoptosis leads to heart disease. For 
example, it is known that hearts of normal rodents and humans present a baseline frequency 
of apoptosis of 1 - 10 apoptotic cells/10
5 
nuclei (162), while only 23 apoptotic cells/10
5 
nuclei 
are able to induce a lethal, dilated cardiomyopathy in mice (163). Kitsis and Mann (177) 
claim that there are still critical gaps in knowledge concerning the true rates of cardiac 
myocyte apoptosis in heart failure as well as the mechanisms controlling it. As apoptosis is an 
asynchronous process, single apoptosis endpoint measurements do not provide enough 
information about dynamics and extent of apoptosis. The only way to detect these small 
changes in apoptosis rates, which can lead to heart diseases, is by in vivo-imaging of the heart 
using probes that can identify cells in different stages of the apoptosis cascade.  
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As it was validated in this work, the sA5-YFP system allows the quantitative, in vivo imaging 
of apoptotic cells during development (Figs. 33-35). Therefore, it can be used to monitor 
natural occurring and ectopic levels of apoptosis over time. Fluorescence labeled Annexin V 
has been proven to be a suitable imaging marker of cardiovascular risk and apoptosis (151). 
Dumont and colleagues (149) could visualize membrane changes of single cardiomyocytes 
undergoing apoptosis in adult mouse hearts with an ischemia-reperfusion injury in real-time 
by Annexin-V-Oregon Green (Anx-V-OG). Similarly, high uptake of radiolabeled Annexin V 
has been found in rabbit, swine and human hearts with atherosclerosis, left ventricular 
dysfunction and ischemia reperfusion (151, 178-181). The greatest disadvantages of the 
systemic injection of Annexin V into adult animals are its elevated cost derived from high 
concentrations needed to penetrate the tissues and the variation in signal intensity depending 
on the efficacy of the injection protocol (99). In contrast, the genetically encoded aA5-YFP 
system expresses continuously the protein, thereby avoiding these problems. It detects clearly 
apoptotic signals in vivo, ex vivo and in fixed tissue sections. In addition, it can be crossed 
with mouse models of cell death and heart disorders to get further insights into the 
mechanisms of apoptosis. 
 
4.7. Limitations of the sA5-YFP system as apoptosis marker during mouse development 
There are some limitations concerning the detection of apoptosis by the sA5-YFP reporter 
system. First, the sA5-YFP detection specificity is determined by the time kinetics of 
phosphatidylserine (PS) externalization on the surface of the apoptotic cell membrane. Taking 
into account that PS distribution varies in each cell type, that the mechanisms of 
externalization are not completely understood (182) and that in this model A5-YFP is secreted 
to the extracellular space, it cannot be assured that sA5-YFP will not bind to intracellular PS. 
It has been shown that intracellular PS is mainly distributed in the inner plasma membrane, 
nuclear membrane, endoplasmic reticulum and secretory vesicles (182, 183). For instance, I 
identified two types of sA5-YFP
+
 signals in sA5-YFP heart sections at E10.5 – E11.5: bright 
punctate sA5-YFP
+
 cytoplasmic signals and the typical sA5-YFP membrane ring-like signal. 
This can be explained by recent evidence showing that extensive plasma membrane-derived 
cytoplasmic vesicles are formed during apoptosis (182). However, as it was not verified that 
these cytoplasmic signals were apoptotic cells, I defined only clear and bright sA5-YFP
+
 
signals surrounding the cell membrane as apoptotic cells or blebs for quantification. 
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Another issue related to the dynamics of PS externalization is the difficulty in defining the 
exact time in which sA5-YFP will bind to PS in different apoptotic tissues. In sA5-YFP 
embryoid bodies and transgenic mouse hearts, the co-localization of sA5-YFP with cCasp3 
was not 100%. This may be due to different possible reasons. First, the exposure of PS to the 
outer membrane of apoptotic cells occurs before or later than caspase-3 activation (69, 184, 
185). Second, sA5-YFP detects apoptotic blebs where cleaved caspase-3 is not present due to 
its different distribution in the numerous membrane blebs formed after fragmentation. Third, 
YFP
+
 signals may co-localize with other executing caspases such as cleaved caspase 7 or 6. 
And finally, the sA5-YFP detection is caspase independent indicating that Annexin V detects 
other types of cell death such as necrosis or necroptosis (186, 187).  
 
The potential binding of Annexin V to necrotic, oncotic cells (65, 142, 181) or to cells 
undergoing other programmed cell death types such as necroptosis (188), pharanathos or 
netosis (8) can be seen as a drawback in its specificity. It is known that apoptosis and 
necroptosis may occur in the same organ (79). In this work, it was proven in transgenic ESCs 
that the sA5-YFP system detects caspase independent cell death after inhibition of caspases 
(Fig. 17). However, it was not possible to detect necroptosis by the pan-caspases inhibitor 
zVAD-fmk in sA5-YFP embryos during neural tube closure (these experiments were 
performed by Prof. Miura and Dr. Yoshifumi; data not shown). This result could be due to 
low tissue penetration of the drug. Therefore, further experiments in the future are needed to 
confirm in vivo, the results observed in the sA5-YFP mESCs. One way to confirm that 
caspase independent cell death occurs in the embryonic heart, the sA5-YFP mouse model 
should be crossed with knockout models of necroptosis (e.g. RIPK3 or MLKL deficient mice) 
(89). If in these mice the amount of sA5-YFP
+
 particles is less than in transgenic sA5-YFP 
embryonic hearts, then necroptosis should be present together with apoptosis during mouse 
heart development. On the contrary, if the number of sA5-YFP
+
 particles is approximately the 
same than in sA5-YFP hearts, then it means that only apoptosis takes place.  
 
Despite these restrictions, the sA5-YFP system used with time lapse imaging is more 
advantageous in comparison to one time-point apoptosis detection methods. Approximately 
two fold more sA5-YFP signals than cCasp3 signals could be detected (Fig. 31), indicating 
that this system allows the detection of a broader spectrum of apoptosis stages. In addition, 
the sA5-YFP transgenic mouse allows the in-vivo monitoring of apoptotic cells and blebs in 
early to late apoptotic stage during mouse embryonic development. Moreover, its potential to 
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detect caspase independent cell death can help to elucidate different programmed cell death 
mechanisms occurring under physiological and non-physiological conditions in the embryonic 
mouse heart.  
 
The feasibility of the sA5-YFP reporter to study apoptosis in healthy postnatal and adult 
mouse hearts and after acute myocardial infarction remains to be validated. Based on 
preliminary analysis, I could observe that apoptosis rates significantly decreased in P2 hearts 
and that it was scarcely present in the adult heart (Fig. 32). However, as the focus of this study 
was the embryonic heart, a deeper characterization of the sA5-YFP signals in the adult heart 
has to be performed. First, it needs to be assessed carefully, whether the strong sA5-YFP 
expression in muscle cells driven by the chicken β-actin promoter with CMV enhancer 
element (CAG) (189) allows to distinguish bright sA5-YFP
+
 signals from ―background‖ 
expression. I found in these preliminary experiments the background fluorescence to be quite 
high probably because of the prominent release of the transgene product into the extracellular 
space. In addition, also co-localization of these signals with cCasp3 should be performed. 
Afterwards, in case that the signal to noise ratios is sufficient to detect proper apoptotic 
signals, it would be very interesting to evaluate if apoptosis is induced after ischemia-
reperfusion as it has been reported before (149). As discussed in section 4.2 there is a huge 
discrepancy in the reported numbers of apoptotic cells present in the diseased heart and it is 
still unclear whether apoptosis is the main cell death mechanism after infarction (20).  
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4.8. Outlook 
This work has confirmed and extended the current literature about apoptosis rates and 
localization of apoptotic cells during mouse heart development. Using the sA5-YFP reporter 
system, it was possible to report that less than 1.5% of the cells in the embryonic heart 
undergo physiological apoptosis. For the first time, it was shown that apoptosis is common at 
early stages of heart development starting from E9.5. It was confirmed that apoptosis rates 
decrease as the heart ages. Furthermore, it was clearly observed that apoptosis is highly 
present in the ventricular trabeculae and in other regions such as the outflow tract, 
interventricular septum, and atria. However, there are still some questions to be addressed to 
understand the role of apoptosis during mouse heart development. For example, it would be 
insightful to know which apoptosis pathway, intrinsic or extrinsic, correlates with the sA5-
YFP
+
 apoptotic cells and blebs. This would help to better design treatments based on 
apoptosis regulation for cardiovascular diseases. 
 
Previous research suggests that both mechanisms control apoptosis in different areas of the 
heart during embryogenesis (190, 191). For example, expression of Fas and FasL, both 
members of the death receptor family that activate the extrinsic apoptosis pathway, was found 
in atria and ventricles, but not in the outflow tract septum or endocardial cushions (43). Other 
studies have shown that pro-apoptotic members of the Bcl-2 family (e.g. Bax and Bik), which 
regulate the mitochondrial or intrinsic apoptosis pathway, are also expressed in the embryonic 
heart (44, 63, 159) in patterns similar to apoptotic cells labeled with TUNEL. To confirm 
these results, it is not only necessary to show a correlation of these proteins in the apoptotic 
regions, but a clear co-localization with apoptotic cells. The sA5-YFP system is suitable to 
assess this issue. In fact, in this work, I showed that labeled sA5-YFP apoptotic cells co-
localized with cleaved caspase 8, a member of the extrinsic apoptotic pathway, in E10.5 
embryos. In a similar way, expression of Bax or Bik and cleaved caspase 9 can be correlated 
to sA5-YFP positive to show that the intrinsic pathway is involved.  
 
Another question to be answered is if the sA5-YFP system detects caspase independent cell 
death in tissues. This can be monitored by in-vivo confocal imaging of sA5-YFP embryos at 
E8.5 – E9.5 after inhibition of caspases using the z-VAD-fmk inhibitor. This pan-caspase 
inhibitor has been widely used to detect caspase independent cell death and necroptosis (86, 
188, 192). If bright sA5-YFP
+ 
signals are still detected after caspase inhibition then the system 
can detect other programmed cell death types. As it has been recently identified that 
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autophagic cell death occurs during heart organogenesis (95), it will not be surprising to find 
an interplay between apoptosis, necroptosis and autophagic cell death regulating cardiac 
morphogenesis.  
 
These caspase inhibition experiments can also be performed to investigate if downregulation 
of apoptosis in the embryonic heart leads to hypertrabeculation or ventricular chamber 
malformation. Watanabe and colleagues have shown that inhibition of apoptosis in the chick 
embryonic heart leads to abnormal outflow tract shortening and ventriculo-arterial 
connections, associated with congenital conal heart defects (54). This together with the 
assessment of gene expression patterns for genes involved in trabeculae formation can help to 
elucidate the role of apoptosis during heart development.  
 
In conclusion, the CAG-sA5-YFP system has the potential to mark apoptotic cells in different 
tissues and cell types. This makes it feasible to explore not only the role of apoptosis in mouse 
heart development but also in a variety of diseases. In addition, it can be crossed with 
different knockout models of apoptosis genes to reveal mechanistic insights and new 
modulators of the apoptosis cascade that may be used as therapeutic targets. 
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6. SUMMARY 
All living organisms face death since the beginning of their lives. Cells commit suicide to 
sculpt correctly all organs during animal development. Currently, there exist at least 13 cell 
death modalities through which a cell is programmed to die. From these, the most studied is 
apoptosis. Despite the huge progress made in the field of apoptosis, little is known about its 
role in mouse heart development and it is still not clear if its upregulation or downregulation 
can lead to heart disease. One of the main reasons for this uncertainty is the lack of techniques 
that mark apoptotic cells at different time points in vivo and in fixed tissue. With a specific 
and broad detection method that overcomes the asynchrony and rapidity in which apoptotic 
cells die and disappear from tissues, it should be possible to confirm if apoptosis takes place 
during mouse heart development, in which areas and at which specific rates occurs during 
different embryonic stages and which are the cells that undergo apoptosis during heart 
morphogenesis.  
 
In this work, I addressed these issues by establishing a genetically encoded reporter tool used 
to visualize and quantify apoptosis during mouse heart development in vivo. This system is 
based on the detection of phosphatidylserine (PS) residues—exposed in the outer membrane 
of apoptotic cells—by Annexin V (A5). Commercial probes of A5 linked to fluorescent 
probes have been developed. These probes provide excellent results in cells, but have some 
limitations such as high cost and not-specific for fixed tissue, when used in fixed tissue or in 
living organisms by systemic injection. Therefore, this system was aimed to overcome these 
drawbacks by ubiquitously expressing a secreted human Annexin V (sA5) fused to the yellow 
fluorescent protein (YFP). The ubiquitous expression was ensured by the chicken β-actin 
promoter with CMV enhancer element (CAG). As cells undergo apoptosis, sA5-YFP binds 
with high affinity to its PS residues resulting in bright fluorescent signals. In this way, it was 
possible to better characterize, quantify and monitor apoptotic signals in the developing 
mouse heart over time. 
 
In summary, this study consisted of two major goals. The first one was to validate the sA5-
YFP system, in vitro and in vivo, to specifically label apoptotic cells. The second goal was to 
use this system to describe the apoptotic patterns and rates during all stages of embryonic 
heart development in more detail. For the first part, I could show that the labeled sA5-YFP 
signals in transgenic mESCs, in EBs, and in sA5-YFP mice were apoptotic cells after 
inducing apoptosis ectopically or in entities (EBs and embryonic tissue such as neural tube,  
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otic placode and yolk sac) in which apoptosis is a physiological process. These cells presented 
the typical morphological and biochemical changes of apoptotic cells. They rounded up, 
detached from the culture plate or tissue compound, formed membrane blebs or fragmented, 
and displayed condensed chromatin. Moreover, the sA5-YFP protein co-localized with active 
forms of pro-caspases (casp-8), effector caspases (active casp-3 and 7) and with TUNEL 
staining. Thus, I proved that the sA5-YFP system allows the visualization of cells and blebs 
(fragments of apoptotic cells) in different stages (early-intermediate-late) of apoptosis.  
 
For the second goal, I used the transgenic CAG-sA5-YFP mouse line to provide detailed 
information about apoptosis rates, distribution of apoptotic events and cells undergoing 
apoptosis during mouse heart development. I could show that apoptosis takes place at all 
stages of the mouse heart development starting from E9.5. I observed than less than 1.5% of 
the cells in the embryonic heart undergo physiological apoptosis and the apoptosis rates 
decrease as the heart ages. In contrast to earlier studies, apoptotic cells were observed very 
clearly in the primitive ventricle at E9.5 and in the lining of the trabeculae of both ventricles 
from E10.5 - E14.5 in sA5-YFP hearts. These events coincide with episodes of trabeculae 
formation, differentiation, remodeling, and compaction, suggesting that apoptosis might be 
necessary for chamber maturation. In addition, I noticed apoptotic events in the outflow tract, 
the interventricular septum, and atria, coinciding with previous reports. Lastly, I demonstrated 
that the labeled sA5-YFP apoptotic cells, found in the trabeculae, co-localize mainly with 
cardiomyocytes around days E13.5 - E14.5 of mouse heart development. These findings 
imply a role of cardiomyocyte apoptosis in ventricular differentiation. However, more 
experiments are needed to undercover the biological role of apoptosis in trabeculae formation.  
 
Last but not least, I provided evidence that the CAG-sA5-YFP mouse model enables the real-
time imaging of induced apoptosis and physiological occurring apoptosis in the developing 
mouse embryo at E8.75 and in the embryonic mouse heart at E9. Apoptotic signals can be 
identified by their roundish morphology and bright sA5-YFP
+
 signals. Fluorescence intensity 
of sA5-YFP can be used as quantitative parameter to evaluate changes in apoptosis in vivo. 
This means that this reporter line can be used to monitor the distribution and morphological 
changes of apoptotic cells within specific tissues over time in living organisms. In conclusion, 
the sA5-YFP mouse has the potential to unravel the physiological role of apoptosis in the 
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developing heart, its role in the formation of other mammalian organs, and in diseases 
displaying aberrant patterns of apoptosis.  
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8. ABBREVIATIONS 
A atria 
Afl autofluorescence 
AIF apoptosis-inducing factor 
ALS Amyotrophic Lateral Sclerosis 
AO acridine orange 
Apaf1 apoptotic protease-activating factor 1 
AR antigen retrieval 
α-SMCs alpha smooth muscle cells 
ASMAC alpha smooth muscle actin  
Atgs autophagy related genes 
AVC atrioventricular canal 
A5 annexin A5 
Bak Bcl-2 antagonist/killer 1 
Bax Bcl-2-associated X protein, apoptosis regulator 
Bcl-2 B-cell lymphoma 2, apoptosis regulator 
Bcl-XL B-cell lymphoma X long, apoptosis regulator 
BF bright field 
Bid BH3-interacting domain death agonist 
Bmp10 bone morphogenetic protein 10 
CAG chicken β-actin promoter with CMV enhancer element 
Casp caspase 
cCasp cleaved caspase 
CD cluster of differentiation 
CD1-Tg CD1 mice-transgenic 
CDH congenital heart diseases 
CED identified cell-death gene 
CIAP calf Intestine alkaline phosphatase 
cIAPS cellular inhibitors of apoptosis 
c-FLIP cellular FLICE-like inhibitory protein 
CMs cardiomyocytes 
CO2 carbon dioxide 
Ct threshold cycle 
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cytC cytochrome c 
DAI DNA-dependent activator of interferon regulatory factor 
DEVD caspase 3-cleavage site: Asp-Glu-Val-Asp 
DIABLO  direct IAP-binding protein with low pI 
DISC death-inducing signaling complex 
DMSO dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide triphosphate 
DPBS Dulbecco’s Phosphate-Buffered Saline 
DR death receptor  
DS donkey serum 
E embryonic day 
EBs Embryiod bodies 
ECFP enhanced cyan fluorescent protein 
EDTA Ethylenediaminetetraacetic acid 
eGFP enhanced green fluorescent protein 
ERBB2 Receptor tyrosine-protein kinase 2 
EtBr ethidium bromide 
FADD Fas-associated death domain protein 
FAM Carboxyfluorescein 
FasL Fas Ligand  
FCS fetal calf serum 
FHF first heart field 
FKBP12 Peptidyl-prolyl cis-trans isomerase 
FMK Fluoromethyl ketone 
FRET Fluorescence resonance energy transfer 
Fw forward primer 
GFP green fluorescent protein 
hA5 human annexin A5 
HIV human immunodeficiency virus 
HS4 Chromatin insulator: chicken β-globin locus control region 
hypersensitive site 4 
IAP  inhibitors of apoptosis 
IMDM Iscove’s Modified Dulbecco’s Medium 
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iVS intraventricular septum 
KO-DMEM Knockout Dulbecco’s Modified Eagle Medium 
LA left atrium 
LED light-emitting diode 
LIF Leukemia inhibiting factor 
LTR LysoTracker Red 
LV left ventricle 
LVNC left ventricular non-compaction 
MEM Non-Essential Aminoacids 
mESCs Mouse embryonic stem cells 
MF20 anti-myosin heavy chain monoclonal Clone MF20 
MGB minor groove binder probes 
MLS Mitochondrial Leader Sequence 
MLKL Pseudokinase mixed lineage kinase domain-like 
MOMP Mitochondrial outer membrane permeabilization 
MOPS 3-Morpholinopropanesulfonic Acid 
N Nuclei 
NBS Nile blue sulfate 
NCCD Nomenclature Committee on Cell Death 
Nec-1 Necrostatin 1 
Neo3 Neomycin resistant cassette 
NF-kβ Nuclear factor kappa-light-chain-enhancer of activated B cells 
NIH National Institute of Health 
Nkx2.5 Homeobox 5-containing transcription factor 
NR Neutral red 
NRG1 Neuregulin-1 
OFT Outflow Tract 
4-OHT 4-hydroxytamoxifen 
P postnatal day 
pBH Bleeding heart vector 
PBS Phosphate-Buffered Saline 
PCD Programmed Cell Death 
PCR Polymerase chain reaction 
PECAM Platelet endothelial cell adhesion molecule 
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PFA Paraformaldehyde 
PMEF-NL Embryonic Fibroblast 
PS Phosphatidylserine 
RA right atrium 
Rev reverse primer 
RIPK1/3 Receptor-interacting protein kinase-1/3 
RNA Ribonucleic acid 
RT Room temperature 
RT-qPCR real-time quantitative PCR 
RV right ventricle 
sA5 secreted Annexin A5 
SHF secondary heart field 
Smac  second mitochondria derived activator of caspases 
SV sinus venosus 
SV129;BL/6 substrain 129;black six mice 
TAE Tris-Acetate-EDTA 
TdT Terminal deoxynucleotidyl transferase 
TEM Transmission electron microscopy 
TFRC Transferrin receptor gene 
TMRM Tetramethylrhodamine methylester 
TNF Tumor Necrosis Factor  
TNFα Tumor necrosis factor alpha 
TNFR1 Tumor necrosis factor receptor 1 
Tr Trabeculae 
TRADD Tumor necrosis factor receptor type 1-associated death domain protein 
TRIF Toll/IL-1 receptor domain-containing adaptor inducing IFN-β 
Tris-HCl Tris-(Hydroxymethyl)-Aminomethan-Hydrochlorid 
TUNEL  Terminal deoxynucleotidyl transferase dUTP nick end labeling 
UAS Upstream Activating Sequences, DNA-binding motif of GAL4 
V ventricle 
Vps34 Phosphoinositide 3-kinase (PI3K) class III isoform 
YFP yellow fluorescent protein 
zVAD-fmk N-benzyloxycarbonyl-Val-Ala-Asp- fluoromethyl ketone 
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